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A B S T R A C T
Microbial keratitis is a sight-threatening ocular infection caused by bacteria, fungi, and protist pathogens. Epithelial
defects and injuries are key predisposing factors making the eye susceptible to corneal pathogens. Among bacterial
pathogens, the most common agents responsible for keratitis include Staphylococcus aureus, Pseudomonas aeruginosa,
Streptococcus pneumonia and Serratia species. Fungal agents of corneal infections include both filamentous as well
as yeast, including Fusarium, Aspergillus, Phaeohyphomycetes, Curvularia, Paecilomyces, Scedosporium and Candida
species, while in protists, Acanthamoeba spp. are responsible for causing ocular disease. Clinical features include red-
ness, pain, tearing, blur vision and inflammation but symptoms vary depending on the causative agent. The underlying
molecular mechanisms associated with microbial pathogenesis include virulence factors as well as the host factors that
aid in the progression of keratitis, resulting in damage to the ocular tissue. The treatment therefore should focus not only
on the elimination of the culprit but also on the neutralization of virulence factors to minimize the damage, in addition to
repairing the damaged tissue. A complete understanding of the pathogenesis of microbial keratitis will lead to the ratio-
nal development of therapeutic interventions. This is a timely review of our current understanding of the advances made
in this field in a comprehensible manner. Coupled with the recently available genome sequence information and high
throughput genomics technology, and the availability of innovative approaches, this will stimulate interest in this field.
© 2016 Published by Elsevier Ltd.
1. Introduction
The unique structure of the human eye along with its exposure
to environment, renders it susceptible to a number of agents respon-
sible for causing infection. Injuries and epithelial defects impair de-
fense mechanisms and exposure to pathogenic microbes can lead to
corneal inflammation or keratitis. The intact ocular surface thwarts
most microorganisms but once anatomical barriers are breached, host
defenses against pathogens are less than sufficient to prevent infection
that can lead to eventual loss of vision. Microbial or infectious ker-
atitis is a potentially sight-threatening ocular condition caused by bac-
teria, fungi, protists etc. It is the inflammation of the cornea caused
by pathogenic microbes that eventually invades the corneal stroma
causing inflammation, and ultimately destruction of these structures
[7,210]. The most common pre-disposing factors to develop infec-
tious keratitis include the use of contact lenses, especially overnight or
extended wear lenses, inadequate disinfecting solutions, trauma, oc-
ular surgery especially corneal surgery, chronic ocular surface dis-
ease, systemic disease like diabetes mellitus and/or extended use of
topical corticosteroids [180,210]. Patients usually present with red-
ness, tearing, rapid onset of pain and blur vision. Clinical presenta-
tion may vary depending on the causative agent responsible for caus-
ing keratitis. The condition should be treated as a medical emergency
and adequate treatment should commence promptly. If appropriate
antimicrobial treatment is delayed, only 50% of the eye gains good
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visual acuity [83]. Appropriate management and timely onset of treat-
ment can reduce the incidence of severe visual loss restricting corneal
damage. Here, we present a concise review of the bacterial, fungal
and protist keratitis. Numerous microorganisms can infect the eye ei-
ther by direct or indirect introduction into the eye. The most common
clinically important microorganisms involved in eye infections are re-
viewed in this article with relation to the anatomical part of the eye in-
volved in the disease, along with a discussion of the pathogenic mech-
anisms and management of the disease.
2. Acanthamoeba keratitis
Acanthamoeba keratitis is a rare but sight threatening corneal in-
fection, caused by an opportunistic protist pathogen belonging to the
genus Acanthamoeba. They are ubiquitous, free-living protists dis-
persed in a variety of environments including air, soil, freshwater, tap
water, hospital equipments, surgical instruments, showers, ventilation
ducts, air-conditioning units, chlorinated swimming pools, sewage etc.
[37]; (Kilvington & White, 1994). Phenotypic switching into a cyst
form enables Acanthamoeba to withstand adverse environmental con-
ditions. The Acanthamoeba trophozoite has an amoeboid shape that
contains spike-like structures known as acanthopodia and during this
stage, amoebae feed and reproduce under favourable environmen-
tal conditions [111,206]. However, under extreme situations such as
lack of nutrients, hyperosmolarity, desiccation, extreme pH, temper-
atures, and the presence of antimicrobials; the trophozoite rounds up
and confines itself within a double-walled resistant cyst form that has
minimal metabolic activity. The cyst stage presents a major prob-
lem in the successful treatment of Acanthamoeba infections as they
http://dx.doi.org/10.1016/j.micpath.2016.12.013
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are resistant to various antimicrobial agents, often leading to recur-
rence of the disease upon discontinuation of therapy [130]. Although
exposure to Acanthamoeba spp. appears to be common due to its ubiq-
uitous nature, the incidence of Acanthamoeba keratitis is less com-
mon. The main risk factors for Acanthamoeba keratitis are contact lens
wear for extended periods, corneal trauma, non-sterile contact lens
rinsing, swimming while wearing contact lenses and biofilm forma-
tion on contact lens [111,198]. While contact lens wear is the lead-
ing risk factor, Acanthamoeba can cause keratitis in non-contact lens
wearers as well [36]. However, it is often overlooked in non-CLs users
as a causative agent of keratitis, where it is usually associated with
trauma and/or exposure to contaminated water, soil and organic mat-
ter. In addition, Acanthamoeba keratitis has been reported after inva-
sive or radial keratoplasty and/or laser-assisted in situ keratomileusis
(LASIK) where the lesions generally worsen due to a delay in the di-
agnosis and treatment [49,170].
Clinical manifestations of Acanthamoeba keratitis include excruci-
ating pain characterized by redness, epiphora, lacrimation, eyelid dip-
tosis, conjonctival hyperhemia, foreign body sensation and photopho-
bia [110,130]; [3,4]. As the disease progresses, stromal involvement
results in infiltration of inflammatory cells displaying a characteris-
tic ring infiltrate. If not promptly diagnosed and treated aggressively,
cornea becomes ulcerated leading to perforation, ring infiltrate, stro-
mal abscess formation, loss of visual acuity and eventually blindness
and enucleation.
Acanthamoeba was first recognized as an ocular pathogen in 1973
in the U.S.A where the first case was reported by an ocular microbiol-
ogy group in Dallas [28]. However, the first published report of Acan-
thamoeba keratitis emerged in the UK in 1974 and was associated
with minor eye injury [128]. The first case in a contact lens wearer
was reported 10 years later in 1984 from a patient wearing soft con-
tact lenses [165]. Since then the number of cases has been on the rise
especially in recent years, mainly due to an increase in the number of
contact lens users, better diagnostics and increased awareness.
2.1. Pathogenesis
2.1.1. Adhesion
The first step in the pathogenesis of Acanthamoeba keratitis is the
ability of amoebae to bind to the corneal epithelium, a factor that de-
termines the degree of pathogenicity of different isolates. The patho-
genic cascade begins via amoebal binding to mannose glycoproteins
on the corneal surface through adhesin expressed on the trophozoite
membrane called the mannose-binding protein (MBP) [29,47,138].
This adherence is a crucial prerequisite for producing infection. In
addition. mild trauma or corneal abrasion is required for the estab-
lishment of corneal infection. Abrasion or trauma results in increased
expression of mannose glycoproteins on the corneal epithelium and
hence there is increased adhesion of amoebae to the damaged cornea,
compared with the healthy cornea [29]. The contact lenses, in addi-
tion to serving as a vector for the introduction of trophozoite onto the
corneal surface, also up regulate mannose glycoproteins on the corneal
epithelium. This results in an increased number of trophozoites bind-
ing to the contact lens-conditioned cornea compared to the normal
cornea thus leading to findings that more than 80% of Acanthamoeba
keratitis cases are associated with the use of CLs [5].
The second important element involved in adhesion is the num-
ber of acanthopodia on the amoebic surface. Pathogenic amoebae have
more than 100 acanthopodia/cell compared to non-pathogenic amoe-
bae. Therefore, non-pathogenic amoeba present very low binding lev-
els to host cells compared to pathogenic amoebae [89,138]. Hence
the number of acanthopodia is also believed to be closely related to
the rate of adhesion to the corneal surface. Once attached, intracellu-
lar signaling processes trigger the pathogenic cascade involved in the
pathogenesis of Acanthamoeba keratitis.
2.1.2. Cytopathic effect
Trophozoite binding to corneal surface is tailed by extensive
desquamation of the corneal epithelium, leading to penetration of the
underlying Bowman's membrane. Trophozoite-mediated cytopathic
effect proceed via several mechanisms such as direct cytolysis, phago-
cytosis and apoptosis [2]. It has been observed that Acan-
thamoeba-mediated direct cytolysis is dependent on calcium channel
activity and on cytoskeletal elements, as the inhibition of both via
the calcium channel blocker, Bepridil and actin polymerization in-
hibitor, cytochalasin D overcomes Acanthamoeba-mediated cytolysis
by over 98% [190]. In addition the presence of structures like food
cups or amoebastomes on the surface of Acanthamoeba suggests that
the amoeba binding to host cells leads to secondary events like phago-
cytosis by which the amoeba bites or engulfs host cells. It has been
observed that Acanthamoeba phagocytose and/or engulfs corneal ep-
ithelial cells and that this activity is mediated via amoebastomes pre-
sent on the surface of amoebae [89].
Apart from inducing direct cell death, several studies indicate that
Acanthamoeba induces apoptosis of keratocytes, iris ciliary body
cells, retinal pigment epithelial cells, corneal epithelial cells, neu-
roblastoma cells etc. [30,111,130,181]. Acanthamoeba induces mem-
brane blebbing, formation of apoptotic bodies, DNA laddering, nu-
clear chromatin condensation of host cell, all known markers for apop-
tosis [3,4]; [148]. It has been observed that exposure to mannose stim-
ulates the production of a 133-kDa protease termed mannose-induced
protein (MIP133) by Acanthamoeba trophozoites. This production of
MIP133 appears to be another vital element of the pathogenic cascade
of Acanthamoeba keratitis. It initiates apoptosis of corneal epithelial
cells in a caspase-3-dependent pathway in vitro and it is possible that
the trophozoite uses this pathway in the desquamation of the corneal
epithelial cells in vivo [70,71]. Furthermore, clinical isolates of Acan-
thamoeba but not soil isolates produce MIP133 and can cause dis-
ease in animals, signifying an association between MIP133 production
and pathogenic potential. Hence the trophozoite-mediated cytopathic
effect to destroy epithelial cells occurs by three independent mecha-
nisms i.e., direct cytolysis, phagocytosis and apoptosis.
2.1.3. Stromal invasion
Following binding and desquamation of the corneal epithelium,
the next step in Acanthamoeba keratitis involves the penetration and
dissolution of the underlying collagenous stroma. The Acanthamoeba
trophozoites secrete a variety of proteases with nonspecific col-
lagenolytic activity to facilitate the invasion and degradation of
stroma. These include serine proteases, cysteine proteases, metallo-
proteinases, elastase, collagenolytic enzyme, phospholipase A and
a novel plasminogen activator [24,27,58]. Studies have shown the
direct role of extracellular proteases in Acanthamoeba keratitis by
co-incubating corneal epithelial cells with Acanthamoeba conditioned
medium, which resulted in host cell cytotoxicity [65]. This cyto-
toxic effect was abolished in the presence of a serine protease in-
hibitor, phenylmethylsulfonyl fluoride (PMSF), suggesting a crucial
role played by serine proteases in the pathogenicity of Acanthamoeba
keratitis [38]. Furthermore, pathogenic Acanthamoeba exhibit higher
protease activity compared to non-pathogenic amoebae [91]. More-
over, serine proteases are also able to degrade collagen, fibronectin,
laminin, secretory IgA, IgG, plasminogen, BSA, fibrin, fibrinogen,
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and rabbit corneal proteins [171]. These properties of proteases are
important because collagen type I is the main structural protein in the
corneal stroma which is important for the maintenance of its integrity.
In addition sIgA, the main immunoglobulin in tears and a primary bar-
rier against pathogenic microbes are also degraded by these proteases.
Other extracellular enzymes like elastase and phospholipase A are ca-
pable of degrading connective tissues. These findings suggest that col-
lagenolytic enzymes have a role in corneal lesions and the genera-
tion of ring-like stromal infiltrates which are characteristic features of
Acanthamoeba keratitis [65].
Pathogenic Acanthamoeba can also use plasminogen activator that
is constitutively present in ocular isolates, to catalyze the cleavage of
host plasminogen to plasmin, which in turn activates matrix metal-
loproteinases (MMPs) to degrade components of extracellular matrix
[13,119]. They result in ulceration of normally quiescent cornea by de-
grading the components of basement membrane and extracellular ma-
trix, including type I and II collagens, laminin and fibronectin [140].
Corneal stroma, unlike other extracellular matrices is vital for the nor-
mal functioning of the eye. Its degradation affects normal vision and
can lead to blindness. Studies have also shown that pathogenic isolates
of Acanthamoeba are able to secrete ecto-ATPases which play a role
in protecting the cells from effector cells of the immune system. Sec-
ondly, they play a role in repolarization of the membrane after depo-
larization by an active compound by acting as a proton pump. Lastly,
these enzymes are thought to be related to adherence to the host cell
[171].
2.1.4. Neuritis
Acanthamoeba spp. are highly motile and secrete a plethora of pro-
teases that augment their pathogenesis by desquamating corneal ep-
ithelium, penetrating Bowman's membrane and invading the corneal
stroma. This cascade of events comes to a halt and trophozoites al-
most are never able to penetrate the corneal endothelium and the an-
terior chamber of the eye [29]. However, they seem to cluster around
the corneal nerves producing radial keratoneuritis [5]. Studies have
demonstrated the chemotactic response of Acanthamoeba trophozoites
towards extracts of neuronal cells and neural-crest-derived cells but
not towards the corneal epithelial or stromal cells [149]. Moreover,
in vitro studies have also demonstrated the killing of nerve cells by
trophozoites via direct cytolysis and/or apoptosis [148]. These cyto-
pathic effects contribute to nerve damage and may account for the ex-
cruciating pain experienced by the patient, coupled with this infection
in vivo.
2.2. Treatment
Currently the treatment for Acanthamoeba keratitis involves top-
ical application of cocktail of drugs, as there is no single effective
drug treatment against Acanthamoeba keratitis. This is mainly because
of the degree of virulence of the infecting isolate which is different
for each individual case and therefore makes it impossible to estab-
lish a correlation between in vitro and in vivo efficacies. The best
therapeutic outcomes are expected only when, it is diagnosed early,
treated adequately and aggressively with a high level of patient com-
pliance. Acanthamoeba trophozoites are sensitive to most available
drugs; however the cysts present a major issue in the course of treat-
ment and are the main reason for the recurrence of infection upon dis-
continuation of therapy. Thus, successful management most often ne-
cessitates extended therapy with a combination of well tolerated drugs
with minimal toxicity to hosts cells that results in a favourable visual
consequences with reduced need for surgical interventions.
The most effective topical agents currently used against Acan-
thamoeba trophozoites and cysts are the biguanides (polyhexamethyl-
ene biguanide (PHMB) 0.02–0.06% or chlorhexidine 0.02–0.2%) in
combination with diamidine (propamidine isethionate 0.1% or hexa-
midine 0.1%) [36,90,106,211]. The former drugs are membrane-act-
ing cationic biocides that interact with negatively charged surface pro-
teins of Acanthamoeba resulting in leakage of the cellular components
[146]. The latter however exert their amoebicidal effects via cationic
surface-active properties inducing structural changes resulting in cell
permeability and are effective DNA synthesis inhibitors [39]. In vitro
studies revealed that cationic agents have the best and most constant
amoebicidal and cysticidal activity [42,62]. If these drugs are applied
early on in the development of infection, at high frequency along
with neomycin and 0.15% dibromopropamidine, they show success-
ful prognosis [106]. Hourly drops of PHMB and hexamidine day and
night may be tapered off after 48 h to alleviate epithelial toxicity, to
hourly drops during the day for the next 72 h. This therapy reduces
viable trophozoites when they are more susceptible and prevent them
from turning into fully mature cysts. This treatment is then reduced
to 2-hourly application during the day for the next 3–4 weeks and
then gradually tailored depending on the individual case. Treatment
regimes on average last over a period of 6 months, ranging from 0.5 to
29 months [152].
In the case of inflammation along with persistent infection, cor-
ticosteroids have been implicated however, there use is controver-
sial as they cause suppression of host immune response [106]. Re-
cent reports also point towards the use of the azoles as an adju-
vant to biguanide and diamidine therapy in resistant Acanthamoeba
keratitis cases [11]. Therefore topical and intrastromal voriconalzole
drops (1%) have been used successfully in 3 cases with resistant
Acanthamoeba keratitis. Surgical management via epithelial debride-
ment, corneal graft surgery (keratoplasty) and/or DALK (deep lamel-
lar keratoplasty) may be required in some cases where the corneas
are permanently scarred or where the topical and oral treatments have
failed [25,74,81,144,173]. Recently, photorefractive surgery seems
to be a very promising modality and have been used in four cases
of early stage Acanthamoeba keratitis, where the patients developed
large corneal abscesses in the upper third thickness of stroma [85].
Another relatively new approach is collagen cross-linking which has
shown promising results in clinically [48,92,126]. It is presumed that
collagen probably prevents further tissue damage and prevents repro-
duction of amoebae and hence the patients showed rapid reduction in
ocular symptoms and ulcer size.
[122] recently reported that autophagy inhibitors have anti-amoe-
bic effects and if used with low concentrations of PHMB (0.00125%)
has very low cytopathic effect on human corneal cells and a high
cytopathic effect on Acanthamoeba cells. In addition [9], suggested
photochemotherapeutic strategy against Acanthamoeba infections and
showed that mannose-conjugated porphyrin has the potential for tar-
geted photodynamic therapy of Acanthamoeba infections. Regardless
of significant advances in Acanthamoeba keratitis treatment over the
last decade or so, prevention still seems to be the best option. In addi-
tion, contact lens wearers must be thoroughly educated on the proper
hygiene to handle contact lenses to avoid this serious sight-threatening
infection.
3. Mycotic keratitis
Mycotic keratitis is the fungal infection of the cornea caused by ei-
ther filamentous and/or yeast-like fungi. They may account for more
than 50% of all culture-positive microbial keratitis especially in trop-
ical and sub-tropical countries [129,196,213]. A strong geograph
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ical correlation has been reported to exist between the occurrences of
different types of keratomycosis. For example, the proportion of ker-
atitis due to yeast-like fungi show a tendency to increase towards tem-
perate climates whereas corneal ulcers caused by filamentous fungi
appear to be more common towards tropical latitudes [100].
Filamentous fungi such as Fusarium, Aspergillus, Phaeohy-
phomycetes, Curvularia, Paecilomyces and Scedosporium apiosper-
mum are most commonly associated with keratitis caused by fila-
mentous fungi [196]. However Candida albicans and other Candida
species are most common keratitis-causing yeast-like fungi. Former is
reported to be due to ocular trauma which is usually the most impor-
tant predisposing factor in healthy young males engaged in agricul-
tural or other outdoor activities [53,129,196]. These fungi do not in-
vade the intact cornea and penetration only occurs once the epithelium
is abraded. Traumatizing agents of animal origin or vegetative matter,
soil or dust particle either directly implant fungal conidia on abraded
corneal epithelium for fungal invasion [53,129,196]. The use of cor-
ticosteroids, ocular surgery, ocular surface disease and contact lens
wear has now also been increasingly identified as a significant risk
factor. Conversely, C. albicans and related fungi are only linked to
keratitis when there is a pre-existing ocular condition like insufficient
tear secretion, defective eye closure, or some systemic illness such as
diabetes mellitus or immunosuppression [195]. This form of kerato-
mycosis may also supervene on a pre-existing epithelial defect caused
by herpes keratitis or abrasion due to contaminated contact lenses.
Fungal infections of the cornea need to be promptly addressed to
facilitate full recovery. In case of filamentous fungal keratitis, clinical
manifestations include sudden onset of pain along with photophobia,
discharge with reduced vision and opacity on the surface of the cornea
suggestive of an ulcer [7]. It may involve any part of the cornea and
show firm, sometimes dry elevated slough, hyphate lines extending
into the normal cornea beyond the edge of the ulcers, multifocal gran-
ular or feathery grey-white satellite stromal infiltrates, immune ring,
Descemet's fold and mild iritis [163,178,194,196]. Although each fun-
gal keratitis exhibits these basic features, they may vary depending on
the etiological agent. Severe, chronic filamentous keratitis somewhat
resemble bacterial suppuration and may involve the entire cornea.
However those due to yeast-like and related fungi may resemble bac-
terial keratitis with an overlying epithelial defect, discrete infiltrate
and slow progression [182].
3.1. Mechanism
3.1.1. Adhesion
Interaction of pathogenic fungi with host cells is the key factor
in the pathogenesis of mycotic keratitis. Adherence of microorgan-
isms to host cells is a pre-requisite for the initiation of the infection.
Hence fungal infections of the cornea begin via adhesion of fungi to
the damaged cornea. Fungal pathogens display a variety of adhesins
that are capable of adhering to various cell types and interact with a
variety of host proteins and glycoproteins present in host cells [68].
The outer fibrillar layer of yeast and filamentous fungal cell wall is
composed of mannan or mannoprotein [75,195]. The adhesive manno-
proteins play an essential role in fungal binding to corneal tissues.
These lectin-like proteins recognize D-mannose or mannose glycopro-
teins on the surface of corneal epithelial cells. Damage to the cornea
results in the upregulation of mannose glycoproteins on the corneal
surface [29]; it may therefore play an important role in the adhesion
and pathogenesis of fungal keratitis. Ocular trauma is the most impor-
tant pre-disposing factor in mycotic keratitis [53,129,196]; the absence
of which prevents fungal penetration into the cornea. Thus, the correla
tion of ocular trauma with an increased expression of mannose glyco-
proteins on the corneal surface and presence of adhesive mannopro-
teins on the surface of fungal cell wall is likely involved in the patho-
physiology of fungal keratitis.
The corneal epithelium also possess other potential fungal binding
sites like laminin, fibronectin, collagen etc. which also play a role in
keratitis [195]. [199] demonstrated the importance of an outer fibril-
lar layer of the germ tube in the process of adhesion to plastics. [16]
reported that these major components of the fibrillar cell wall layer
of the germ tube act as a receptor for laminin, fibrinogen and medi-
ates its attachment to membranes. The involvement of specific interac-
tion of Aspergillus fumigatus with finrinogen and its role in cell adhe-
sion has shown that fungal conidia adhere avidly to wells coated with
laminin, fibrinogen, collagen and fibronectin substrates [34]. This was
further supported by Ref. [19]; who showed the ability of fibrinogen
and laminin to inhibit the adherence of conidia to pulmonary epithe-
lial cell lines. In addition sialic-acid dependent lectins have also been
reported to play an important role in recognition of laminin and fib-
rinogen by Aspergillus and Penicillium conidia.
Furthermore, the outer layer of conidia also plays a crucial role in
the early stages of infectious process. The surface of resting conidia
has been reported to have proteins belonging to the hydrophobin fam-
ily [143,191] which are detected in all filamentous fungi and thought
to play a role in adherence [168].
3.1.2. Invasiveness and morphogenesis
The etiological agent in Fusarium keratitis is able to invade the
cornea gaining access to the anterior chamber of the eye. There, at the
pupillary area, it forms a lens-iris-fungal mass affecting the normal
drainage of aqueous humor leading to an increase in the intraocular
pressure causing fungal malignant glaucoma [97]. Initially, malignant
glaucoma was thought to occur only in Fusarium keratitis, however
recently [78]; reported a case of Aspergillus-induced malignant glau-
coma where the uniform shallowing of the anterior chamber was pre-
sent with raised IOP unresponsive to antiglaucoma measures. Eventu-
ally A. flavus was isolated from the anterior chamber of the eye.
Fungal invasiveness is directly related to the fungal load and in-
versely proportional to the intensity of inflammatory response [204].
Therefore, the heavier the load of the fungus, the greater the extent of
invasion and the smaller the number of inflammatory cells. In early
mycotic keratitis, the heavy fungal load with deep tissue penetration
may overcome the inflammatory response in corneal tissue, encour-
aging the progression of the disease. Conversely the inflammatory re-
sponse in early keratitis may be mild and therefore the fungi multiply
extensively and penetrate deep into the tissues. The putative sequence
of events in which it occurs still needs to be confirmed.
Phenotypic switching or morphogenesis is an important method of
adaptation used by some microbes in different microenvironments to
survive inside infected hosts. This permits fungi to survive in the pres-
ence of anti-fungal drugs and resist anti-microbial therapy. The same
intrahyphal hyphae or hypha-in-hypha and thickened fungal cell walls
are seen in corneal tissues infected with L. theobromae and in corneas
infected with F. solani keratitis treated earlier with corticosteroids,
as seen in the presence of antifungal drugs [94,193]. This suggests
that these morphological alterations may allow fungi to evade host de-
fenses and present a barrier against antifungal drugs [77] demonstrated
the role of EFG1-regulated SAP6 gene of C. albicans which encodes
for a unique secreted aspartyl proteinase. They concluded that pro-
teases contribute to corneal pathogenicity in C. albicans keratitis and
are also associated with morphogenic transformation from yeast to in-
vasive filamentous forms.
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3.1.3. Toxigenicity
Various keratitis causing fungi are known to produce mycotoxins;
however their exact role in the pathogenesis of keratitis is still un-
known. Several toxins produced by Fusarium spp. include nivalenol,
T-2 toxin, deoxynivalenol, diacetoxyscirpenol and fusaric acid [157]
studied the relationship of toxin production with the severity of dis-
ease and concluded that toxin production in vitro did not relate to the
clinical presentation of severity of keratitis and the outcome of the
treatment. The toxic effects of aflatoxins on the cornea of chicks has
been established [86]. It was demonstrated that when aflatoxin was ad-
ministered to chicks, haziness of the cornea and separation of corneal
lamellae was observed in addition to infiltration by polymorphonu-
clear leukocytes. [101] demonstrated that A. flavus isolated from ker-
atitis patients produce significantly more aflatoxin compared to those
of the environmental isolates. However the reason behind this phe-
nomenon is unclear and requires further study.
The ability of fungi to produce various enzymes could also damage
tissues, facilitate invasion and eventually influence the severity and
outcome of the disease. [217] examined the role of fungal proteases
in the pathogenesis of mycotic keratitis. It was observed that the clin-
ical isolate of A. flavus, isolated from a patient with severe keratitis,
secrete variety of proteases including serine proteases, cysteine pro-
teases, metalloproteases and concluded that fungal collagenases are
the mediator of the severe corneal destruction observed in keratitis.
When attempted to compare the presence of fungal proteases in vitro
and in vivo, the corneal isolates of A. flavus and F. solani predomi-
nantly secreted serine proteases and little metalloproteases in vitro. In
vivo, however the protease profile shifted to metalloproteases and no
serine protease activity was detected [52]. Matrix metalloproteinases
are thought to play a pathological role in the degradation of extracel-
lular matrix components such as basement membrane collagen; same
as those found in corneal basement membrane and stroma [18]. They
have also been shown to be upregulated in ulcerative fungal keratitis
in rabbit as well as in the tear film of horses with ulcerative keratitis
and hence are thought to play a probable role in the pathogenesis of
fungal keratitis [52,134]. However, the exact role of fungal proteases
in mycotic keratitis needs further investigations.
3.2. Treatment
Fungal keratitis is a complex entity with many considerations when
it comes to treatment. On the whole, treatment generally entails of
chemotherapy consisting of topical and/or systemic drugs, alone or in
combination with surgical treatment. However, in developing coun-
tries with limited care and economical barriers, mycotic keratitis is of
major concern as it can cause visual loss in a demographic popula-
tion that has limited access to care. Each antifungal has its own bene-
fits and limitations and therefore must be selected carefully based on
etiological agent and susceptibility testing. There are several classes
of antifungals available like polyenes, azoles and fluorinated pyrim-
idines, each with their own advantages and disadvantages. Polyenes,
including natamycin, nystatin and amphotericin B, disrupt fungal cell
by binding to the cell wall ergosterol of both filamentous as well
as yeast-like fungi. However their tissue penetrating ability is poor
and therefore is mostly recommended in cases of superficial corneal
infections [7,195]. Administration is every 30 min during the first
24 h and then every hour for the next 24 h and then gradually ta-
pered off according to the response. While amphotericin B is com-
monly administered as a topical solution, intracameral administration
is an effective alternative in reducing time to disappearance of hy
popyon and final improvement [216]. Although active against both
forms of fungi, it has shown variable activity against Fusarium
species. Owing to its side effect profile and lack of coverage against
Fusarium keratitis, it is not considered as a first line agent [7].
Natamycin on the other hand has a broad-spectrum activity against fil-
amentous fungi and is the first line treatment against fungal keratitis
and the drug of choice for Fusarium keratitis. The drug can only be
given topically and hence can only treat superficial fungal keratitis as
opposed to deep stromal fungal invasion. The presence of deep lesions
may therefore require other antifungals like azoles administered via
subconjunctival or intravenous routes [187].
The azoles including imidazoles and triazoles, at low concentra-
tions inhibit ergosterol biosynthesis while, cause direct damage to
cell walls at higher concentrations [188]. Fluconazole and ketocona-
zole show good intraocular penetration and are therefore good agents
against keratitis with deep lesions [137]. They are the preferred treat-
ment against both candida and filamentous fungi however, flucona-
zole has narrow coverage against filamentous organisms but keto-
conazole is active against Aspergillus, Candida as well as Curvularia
species [7,45,154]. Voriconazole is a good alternative with minimal
toxicity and is not only active against Candida but also against fila-
mentous fungi such as Fusarium spp. [99,112]. In refractory FK cases,
topical voriconalzole has been used as an adjunct to natamycin along
with intrastromal injections of voriconalzole with success [61]. [61]
reviewed 40 case-reports and concluded that voriconalzole is a safe al-
ternative against major ocular fungal infections but shouldn't be used
as a single agent for initial treatment.
The fluorinated pyrimidines such as flucytosine etc. are converted
into thymidine analog blocking fungal thymidine synthesis. They are
usually administered with an azole or amphotericin B for synergis-
tic effects and to avoid development of resistance. Subconjunctival
injections have also been used in patients with severe keratitis. Re-
gardless of the drug choice, successful therapy requires prolonged fre-
quent drug administration and therefore adherence of patients to treat-
ment is also an important factor affecting the outcome of treatment.
In addition, liposomal preparation of anti-fungal drugs are also under
trail and has demonstrated some efficacy in rabbit models [1,57]. Fur-
thermore [156] compared the efficacy of topical clotrimazole-β-cy-
clodextrin (CBC), a comparatively new anti-fungal compared to am-
photericin B and concluded that CBC reduces the period of treatment
on average by a duration of 1 week. The authors also reported greater
efficacy of CBC in cases of Candida keratitis.
Surgical interventions are required in case of complications of
acute infectious processes as well as if the disease is refractory to med-
ical management. Penetrating keratoplasty (PK) is the most common
surgical treatment used to excise lesions of the cornea and replaced
with a donor corneal graft in case of refractory or severe cases of fun-
gal keratitis [150]. In addition, it is an effective way to treat corneal
perforations as a result of fungal infections [212]. As an alternative
to PK, debridment is also used where causative agent and necrotizing
material is removed thereby enhancing the penetration of anti-fungal
medications by the removal of epithelium. It is recommended where
the necrotizing tissues are hindrance to the healing of corneal ulcers.
Alternate surgical procedure includes lamellar keratoplasty (LK) in
which only diseased layers of the corneal surface are excised thereby
leaving the underlying structures of the cornea intact. It is recom-
mended when the fungal invasion is only focal [151,158]. In this way,
the risk of endothelial rejection, the most severe type of corneal graft
rejection, is minimized.
The challenging nature of fungal keratitis along with less than
ideal outcome of current treatment regimes, various experimental ad
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vances have also been made. Corneal collagen cross-linking (CXL)
is a relatively new technique currently been investigated in conjunc-
tion with photo-activated riboflavin (PAR) in refractory keratitis cases
[102,137]. Investigations into the use of nanoparticle technology with
terbinafine and silver have also shown promising results [189,214].
In addition, topical aqueous garlic extracts have been tested on rab-
bit keratitis models infected with A. flavus [76]. Nonetheless, fungal
keratitis is a complex entity with many considerations when it comes
to treatment. However, prompt identification of the etiological agent
along with targeted therapy may result in favourable outcome.
4. Bacterial keratitis
The major bacterial agents of infectious keratitis include Staphy-
lococcus aureus, Pseudomonas aeruginosa, Streptococcus pneumonia
and Serratia species [210]. The community acquired cases of bacte-
rial keratitis are usually resolved with an empirical treatment, how-
ever if left un-attempted, may result in perforation, endophthalmitis
and loss of vision [23,210]. Clinical presentation of bacterial keratitis
include acute pain, redness, photophobia and corneal ulceration [179].
Pseudomonas ulcers are more severe at presentation than other bac-
terial ulcers and are often difficult to treat, resulting in worse visual
outcome than other bacterial ulcers [56,183].
Bacterial keratitis accounts for approximately 90% of all microbial
keratitis cases [127] with P. aeruginosa as the most common culprit,
worldwide [40]. Corneal infection of Pseudomonas is most commonly
associated with the use of contact lenses and was rarely reported as
a problem prior to the emergence of contact lens [114,155]. The re-
sistance of Pseudomonas to disinfectants, coupled with its adherence
capability to plastics, facilitates its introduction into the eye where it
can react with defective corneal epithelium, gaining further entrance
into the corneal stroma. S. pneumonia on the other hand is the major
cause of corneal ulcers in developing countries however, some reports
emphasize on the fact that Streptococcus are most commonly encoun-
tered after P. aeruginosa and/or S. aureus eye infections [14,114,215].
Unlike P. aeruginosa, pneumococcal keratitis is not commonly asso-
ciated with the use of contact lenses and the predisposing factors often
include ocular trauma or surgery [31,104,114,125,160,207].
Along with P. aeruginosa, S. aureus is also a common etiological
agent [79,103,114,136,209]. It is a commensal organism that can read-
ily gain access into the eye, given the opportunity [121,174,185]. In-
dividuals whose eyes are compromised due to various reasons includ-
ing ocular surgery or trauma, contact lens use, viral infection or other
eye illnesses are at high risk of developing this infection [26,32,135].
In particular, the ability of S. aureus to develop antibiotic resistance
makes this infection among the most difficult one to treat [10]. This,
along with Serratia marcescens, which once was considered a harm-
less saprophyte, has now been increasingly isolated from the corneal
surfaces of keratitis patients [142]. The isolation rate of S. marcescens
from contact lens-coupled corneal infections ranges from 5 to 28%;
almost comparable to the isolation rate of P. aeruginosa in contact
lens-related keratitis [69,167]. S. marcescens is a motile gram negative
rod abundantly dispersed in nature and contributes to contact lens-re-
lated keratitis [141,142].
4.1. Mechanism
4.1.1. Adhesion
Bacteria initiate infection by engaging with the host cell-surface
receptors via various adhesins, which mediate bacterial binding to
corneal epithelial cells. Microbial adhesins not only play a role in
bacterial attachment to the surface of epithelial cells but may also
play an active role in subsequent interactions and infective process.
They may act as toxins initiating microbial invasion and contribute to
subsequent pathogenic cascade. Bacteria display several adhesins on
their surface such as pili or fimbriae, which recognize specific car-
bohydrates or proteins on the surface of host cell. The adherence of
P. aeruginosa, S. pneumonia and S. aureus is significantly higher to
damaged corneal epithelium compared to other bacteria accounting for
their frequent isolation from keratitis cases.
Studies have shown that purified pili successfully compete with
cold bacteria for binding to ocular surface and have been used to pro-
tect against P. aeruginosa keratitis. Corneal epithelial glycoproteins
act as surface receptor mediating pilus binding activity and amino
sugar sialic acid was able to completely inhibit pilus binding to mouse
corneal epithelial cells [63,164]. Bacterial flagella on the other hand
are filamentous organelles, responsible for bacterial motility and
therefore are also responsible for dissemination of infection. More
than 95% of P. aeruginosa clinical isolates are flagellated and fla-
gella-deficient mutants have been observed to be non-virulent [8].
In addition the anti-flagellar antibody homologous to the infecting
strain protects mice from Pseudomonas corneal infection [164]. Fur-
thermore, the glycocalyx may also play an important role in bacter-
ial adhesion by producing slime aggregates resistant to phagocytosis
thereby enabling them to adhere to cells [72].
S. aureus surface adhesins, collectively known as MSCRAMMS
(microbial surface components recognizing adhesive matrix mole-
cules), have also been recognized to mediate bacterial adherence to
host extracellular matrix components, collagen, fibronectin, fibrino-
gen, laminin and elastin [80]. [161]; studied the role of MSCRAMM
Cna (collagen-binding adhesin) in S. aureus keratitis and concluded
that collagen-binding adhesin is a virulence factor for S. aureus ker-
atitis and is involved in the early events of pathogenesis of S. aureus
infection of the cornea. Similarly, [80] studied the role of S. aureus
fibronectin-binding protein as an epithelial and/or endothelial cell ad-
hesin/invasion protein. Their data suggested that FnBPs is a surface
ligand for human corneal cells and play a key role in host-parasite in-
teractions. It serves as an important adhesin and triggers invasion in
ulcerative keratitis caused by S. aureus.
Likewise, Streptococci colonize different sites on human body
by expressing multiple adhesins and hence their attachment to hu-
man tissues is mediated by a diverse group of bacterial surface pro-
teins, MSCRAMMS [60]. Plasmin and fibronectin binding protein A
(PfbA), a MSCRAMMS, is known to promote adherence and invasion
of bacteria to human epithelial cells by recognizing molecules like fi-
bronectin. In addition, pneumococcal surface adhesin A (PsaA), pneu-
mococcal surface protein A (PspA), pneumolysin (ply), pneumococcal
adherence and virulence factor A (PavA), choline-binding protein A
(CbpA/PcpA), putative protease maturation protein A (PpmA), IgAI
protease (IgAIp), and the streptococcal lipoprotein rotamase A (SIsA)
have all been shown to be associated with pneumococcal adherence
and virulence [153]. Streptococcal cell surface may contain fibrillar
structure like pili and fibrils which may also mediate attachment to
cell surface to initiate infection. The pneumococcal surface protein C
(PspC) promotes adherence and uptake of pneumococci into nasopha-
ryngeal epithelial cells (Hammerschmidt et al., 2000). Also, antibodies
against PsaA which code for pneumococcal surface adhesin A (PsaA)
resulted in reduced adherence to nasopharyngeal epithelial cells [162].
Therefore, these adhesins are likely involved in the initial stages of
Streptococcal ocular infection.
Serratia marcescens on the other hand possess mannose-specific
adhesins, associated with flagella. These adhesins probably interact
with mannose glycoproteins expressed on the surface of corneal ep
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ithelial cells as a result of abrasion or trauma due to the use of contact
lenses. [98]; identified type I fimbriae as the critical adhesin that me-
diate attachment of S. marcescens to human corneal epithelial cell sur-
face. They also identified two AHL (N-acylhomoserine lactone)-regu-
lated genes, bsmA and bsmB, to be involved in adhesion to biotic sur-
face and the expression of these genes leads to the attachment of S.
marcescens to HCE cells. In 2007, Shanks et al. demonstrated the role
of oxyR and type I fimbrial genes and concluded that they are involved
in cell-cell and cell-biotic surface interactions. In addition, two classes
of pili, mannose-resistant and mannose-sensitive pili may also play a
role in the attachment of bacteria to epithelial cells [67].
4.1.2. Bacterial invasion and cytotoxic effects
Once adhered to the epithelial surface, the pathogen invades into
the corneal stroma. This invasion is facilitated via proteases, exotoxins
resulting in degradation of basement membrane and extracellular ma-
trix, causing cells to lyse. A number of exotoxins including heat-sta-
ble haemolysin, phospholipases, exotoxins play a role in invasion of
bacteria into the cornea with eventual stromal necrosis [133]. Once
bacterial invasion into the cornea has ensued, the infection progresses
rapidly towards melting of cornea facilitated by bacterial proteases,
activation of metalloproteases and stimulation of immune response re-
sulting in further damage via release of reactive oxygen intermediates
and host proteases [114,192]. Proteases contribute to the pathogenesis
of keratitis by degrading basement membrane, laminin, proteoglycans,
collagen, and extracellular matrix [66,201].
P. aeruginosa is capable of secreting at least 7 different proteases
including elastase A and B, modified elastase, alkaline protease, pro-
tease IV, P. aeruginosa small protease and large exoprotease, some of
which play a potential role in the pathogenesis of keratitis [113,202].
Metalloproteases especially elastase B (Las B) and alkaline protease
(AP), play a considerable role in keratitis as Las B injection into the
corneal stroma result in significant corneal damage [73,88]. Protease
IV (PIV) on the other hand cleaves variety of host defense proteins
including immunoglobulins, complement components, antimicrobial
peptides and surfactants and hence contributes to the virulence of the
organism [6,44]. Pseudomonas aeruginosa small protease (PASP) is
able to cleave collagen, the chief structural component of the corneal
stroma and hence it could play an important role in the obliteration of
cornea [186]. Purified PASP when injected into the rabbit cornea re-
sulted in the destruction of the epithelium and the formation of ero-
sions that can reach into the stroma. These findings suggest that PIV
provides bacteria with a defense arm against multiple host defense
molecules, while PASP degrads collagen-based structural component
of the eye, thereby mediating the pathophysiology of keratitis.
[120] determined the role of MucD protease of P. aeruginosa in
keratitis in the cornea of mice. The number of bacteria and clinical
score in eyes infected with mucD deficient strain was significantly less
compared to the parent or rescued strain. In addition large number of
infiltrating PMN cells were observed in mucD deficient eyes along
with higher MIP2 levels. It was concluded that MucD protease of P.
aeruginosa suppressed IL-1β, KC and MIP2 as well as inhibited neu-
trophil recruitment in the cornea and hence plays a critical role in P.
aeruginosa keratitis by facilitating the evasion of immune response.
[87] examined the expression of three main exotoxins, ExoS, ExoT
and ExoU, in clinical isolates of P. aeruginosa and showed that major-
ity of strains (84%) were ExoS+ and ExoT + but lacked ExoU. How-
ever, 5 out of 7 strains that were expressing ExoU were also positive
for ExoS which is usually a rare phenotype. These exotoxins are di-
rectly injected into the host cell via type III secretion system of P.
aeruginosa where they exert their cytotoxic effects onto the host
cell (Hauser, 2009). ExoU expressing strains cause rapid cell lysis
whereas, ExoS strains are invasive in nature causing membrane bleb-
bing within epithelial cells which are utilized as a site for bacterial
replication and motility [46].
The capsular polysaccharide of S. pneumoniae which once was
considered the central dogma in pneumococcal virulence is proven to
be untrue in the case of keratitis; as noncapsular strains of S. pneumo-
niae are also able to cause severe keratitis in rabbit keratitis infection
models [131,159]. Other than capsule, the most studied virulence fac-
tor of pneumococcus is pneumolysin, a toxin belonging to the family
of bacterial cholesterol-dependent cytolysin. It causes direct cell dam-
age by binding to the cholesterol in the host cell membrane followed
by polymerization into 30–50 mers, thereby forming pores in the host
cell membranes [124,197]. In addition to forming pores, it initiates
immune-derived damage by activating complement system and in-
duces inflammation [145]. Futhermore, reduced corneal virulence was
demonstrated by of pneumolysin-deficient strain of S. pneumoniae in
a rabbit model of intrastromal infection. It was shown that mutation
in the complement activation domain of pneumolysin resulted in re-
duced polymorphonuclear leukocyte (PMN) recruitment and therefore
less corneal damage and virulence compared to the wild-type strain
[82].
Proteins other than pneumolysin, includes choline-binding proteins
like pneumococcal surface proteins A and C (PspA and PspC), neu-
raminidase A (NanA) and a variety of other surface-associated pro-
teins such as those involved in adherence, immune evasion, activation
and enzymatic reactions have been identified to be involved in non-oc-
ular models of infection Recently a metalloprotease, ZmpC, has been
shown to induce ectodomain shedding of the membrane-associated
mucin (MAM) from conjunctival and corneal epithelial cells leading
to the loss of glycocalyx barrier function and enhanced internalization
of bacterium. It was concluded that the removal of MAMs may serve
to be an important virulence mechanism employed by S. pneumoniae
[54].
The alpha-toxin is a pore-forming lytic cytotoxin produced by
nearly all strains of S. aureus. Once it gains entry into the cytoplasmic
membrane, it moves laterally until seven subunits combine in a circu-
lar arrangement [118,139,205]. The individual toxin molecules inter-
act with cavoline-1, thereby forming pores in the membrane [23] stud-
ied the role of alpha-toxin in the corneal virulence of S. aureus and
concluded that it plays a major role in staphylococcal keratitis, caus-
ing destruction of corneal tissues in the infected eye. Later et al., 1997
showed that even nanogram quantity of purified alpha-toxin causes
extensive sloughing of the rabbit corneal epithelium, corneal edema
and severe iritis. Gamma-toxin, a two component toxin from S. au-
reus is composed of an F component and an S component that are
non-toxic on their own. The S component binds to the target cell fol-
lowed by binding of the F component both of which then move lat-
erally in the cell membrane joining the other F‐S pairs to form a ring
that penetrates the membrane resulting in cell lysis [55,184]. The path-
ogenic role of gamma- and alpha-toxin were determined by Ref. [35]
who illustrated that the virulence of strain, Newman is mediated by
both gamma- and alpha-toxin, with alpha-toxin mediating corneal ep-
ithelial erosions. The strain deficient in either toxins were consider-
ably less virulent compared to parent or rescued strains. S. aureus se-
cretes several two component toxins each of which has its own S and
F components [55]. This two component toxin system of S. aureus is
complicated by the fact that S component of one toxin can also bind
to the F component of the other toxin thereby creating several unique
combinations with their own specific toxicity. The role of these tox-
ins in corneal virulence is yet to be determined. The protein produced
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by setnm-1 gene has been shown to cause extensive corneal damage;
an attribute mediated by its protease activity and is now considered to
be important in the virulence of S. aureus keratitis [21]. In addition,
mutant deficient in this gene is considerably less virulent compared to
its parent or rescued strain [22].
Similarly, intra-corneal injections of sub-microgram amounts of
Serratia metalloprotease were able to elicit a rapid and extensive
corneal tissue damage of rabbit corneas by causing liquefactive necro-
sis and descemetocele formation [95,108]. [109] showed that acute
inflammation, liquefactive necrosis of rabbit cornea and descemeto-
cele formation occurred after intra-corneal injection of Serratia pro-
tease. In addition, they also showed the in vitro solubilization of the
stromal proteoglycan ground substance. Ultramicroscopic examina-
tion of damaged cornea revealed loss of ruthenium red staining of the
proteoglycan ground substance and dispersal of ultra-structurally nor-
mal collagen fibrils. Therefore, the major corneal damage after the
injection of Serratia protease is due to the solubilization and loss of
ground substance of the tissue and the proteases are at least in part
involved in the production of severe corneal damage caused by this
bacterium. [84] identified a 56-kDa protease as one of the major fac-
tors contributing to the pathogenesis and tissue destruction caused by
this bacterium. Vaccination of rabbits with purified protease prepara-
tions from S. marcescens exhibited significantly less corneal destruc-
tion upon corneal encounter with live bacteria, indicating that pro-
teases are important virulence factors during the development of ser-
ratial keratitis [96]. [115] showed that mutant strains of S. marcescens
that are deficient in the production of 56 kDa metalloprotease are con-
siderably less cytotoxic to mammalian cells. It was further revealed
that the culture filtrates of wild-type bacteria pre-treated with EDTA
or 1,10-phenanthroline (inhibitor of metalloproteases) exhibited sig-
nificantly reduced cytotoxicity.
Gram negative lipopolysaccharide is also an important virulence
factor in infectious keratitis. It contributes to the pathogenesis of ker-
atitis by mediating the attachment to the cornea and contact lenses,
bacterial internalization and survival inside corneal epithelial cells. In
addition, it confers resistance to the complement-mediated killing and
stimulates neutrophil migration and infiltration into the cornea with
subsequent corneal scarring and opacification. Also, exopolysaccha-
ride formation by both gram positive and gram negative bacteria re-
sults in local immunosuppressive effects as well as interference with
phagocytosis.
4.1.3. Stromal necrosis and production of ring infiltrate
Bacterial exotoxins and proteases are constitutively released dur-
ing multiplication of bacteria. These toxins and enzymes persist in the
cornea for a prolonged period of time causing continual stromal de-
struction and can deprive eye of its vision. Most exotoxins are heat-la-
bile and have antigenic properties. The LPS, an endotoxin within the
cell wall of gram negative bacteria is released resulting in the produc-
tion of stromal rings. These rings consist of polymorphonuclear leu-
cocytes within the corneal stroma, which are chemo-attracted by the
alternate complement pathway.
4.2. Treatment
Due to the rapid progression of bacterial keratitis, it should be
treated as a medical emergency and empirical antibiotic treatment
should be promptly commenced. The objective for the initial therapy
is the rapid eradication of the corneal pathogen. Basically, no sin-
gle antibiotic is effective against all bacterial keratitis-causing organ-
ism and therefore an agent having broad spectrum activity covering
both, gram negative and gram positive organisms is desirable. Broadly
speaking, two treatment options are available; fluoroquinolones
monotherapy and/or combination therapy of fortified antibiotics in-
cluding cefazolin and tobramycin or gentamicin [51]. The amino-
glycosides in fortified drops provides excellent coverage against
gram-negative organisms and are also active against Staphylococci
and some Streptococci. Cephalosporin on the other hand gives good
coverage for non-penicillinase producing gram-positive bacteria. Flu-
oroquinolone antibiotics have a broad spectrum activity against both
gram-negative and gram-positive organisms including penicilli-
nase-producing and methicillin resistant Staphylococci. They inhibit
DNA gyrase and topoisomerase IV; the key enzymes involved in
DNA replication and transcription leading to bactericidal effect of
these antibiotics [15,147,210].
The frequency of application of antibiotic drops depends on the
severity of infection but usually they are administered every half an
hour for the first 24–36 h [51,133]. In severe cases, an initial load-
ing dose is achieved via a drop every 5 min for the first 30 min. The
concept behind the loading dose is the vascularity of the cornea and
poor penetration of the drug into the corneal stroma which requires
frequent topical applications to achieve minimal inhibitory concentra-
tion. The therapy is then tapered off gradually based on the clinical
response of the patient. Other antibiotics used include amikacin, van-
comycin, methicillin, clotrimoxazole, and clarithromycin depending
on the causative agent responsible for keratitis [51].
Owing to the rich innervation of the cornea, the disease is fre-
quently associated with considerable pain and therefore analgesics
or pain control medications are recommended, which result in im-
proved patient comfort and effective delivery of the treatment regi-
men. The use of corticosteroids as anti-inflammatory agents are con-
troversial and are best avoided until the infection is completely erad-
icated or at least under control [51,133]. In patients with corneal ul-
ceration the use of non-steroidal anti-inflammatory drugs should also
be avoided due to increased risk of corneal melting and perforation.
Topical cycloplegics are used to relieve ciliary spasm, pain and for-
mation of synechiae. Secondary glaucoma may result in keratitis due
to increased intraocular inflammation and hence must be treated with
topical antiglaucoma medications.
In the case of marked corneal ulceration, the temporary use of
therapeutic soft contact lenses may facilitate stromal repair and pro-
mote re-epithelialization by protecting corneal surface from mechan-
ical trauma. They may act as a tear film antibiotic retention device
thereby facilitating penetration by prolonging contact time [20,116].
In addition, collagen corneal shields soaked in antibiotic solution have
also been used as an effective adjunct and have shown to increase an-
tibiotic penetration [132,203]. Furthermore, temporary intracanalicu-
lar collagen implants and liposomal systems have also been designed
to prolong drug retention and interaction [50,166].
Therapy for bacterial keratitis is not only to eradicate the causative
agent but also to prevent tissue destruction and irreversible struc-
tural alterations caused by enzymes and toxins released by the bacte-
ria. Enzyme inhibitors like disodium edetate, acetylcysteine, Heparin
have been shown to be effective experimentally [43,117,172]. Syn-
thetic inhibitors of matrix metalloproteases have been shown to in-
hibit P. aeruginosa proteases in experimental Pseudomonas kerati-
tis [12]. The corneal stroma which constitutes about 90% of corneal
thickness is made up of regularly arranged collagen fibrils. Thus the
collagenases from bacteria, digest the human collagen causing the
cornea to melt. Moreover, collagen cross linking is a useful technique
which uses riboflavin and UVA irradiation to strengthen corneal tis-
sues thereby enhancing its rigidity [175,176,208]. The interaction be-
tween riboflavin and UVA strengthens chemical bond formation be-
tween collagen fibrils and hence increasing its resistance to enzy
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matic digestion [177]. In addition, the photoactivation of riboflavin
has cidal effect on microorganisms by causing damage to microbial
DNA and/or RNA [210].
In case of progressive corneal thinning or perforations, less than
2 mm cyanoacrylate tissue adhesives may be used, which may also
have some inherit antibacterial activity as well [41,51,93,133]. Tissue
adhesives are only suitable for small perforations, as they are toxic to
corneal endothelium. In case of large perforations, therapeutic pene-
trating keratoplasty may be required. Corneal patch grafting may be
an alternative to tissue adhesives and conjunctival flaps may help se-
lected cases of refractory ulceration to assist healing. Severe bacterial
keratitis may also result in cataract formation due to bacterial toxins,
iridocyclitis and treatment toxicity [107]. Surgical intervention may be
required in such cases depending on the degree of corneal scarring and
opacification.
5. Concluding remarks
Microbial keratitis, is a complex entity with many considerations
when it comes to its treatment. It is a major public health concern
particularly in developing countries where access to care is limited
and economic barriers are huge where it can become a leading cause
of visual loss in a population that is young. As with all corneal in-
fections, proper identification of the causative agent followed by ap-
propriate targeted therapy can abate the risk of complications. A bet-
ter understanding of the pathogenic cascade would no doubt lead to
improved clinical treatment. However the emergence of drug-resis-
tant strains along with the recurrence of infections emphasize on the
need for more effective therapeutic modalities. Additionally, the need
to identify the genetic basis of virulence factors responsible for the
disease is also important, as the pathogenicity of keratitis is a sum
of multiple events occurring together in time and space for the suc-
cessful transmission of the pathogen to the susceptible host, overcom-
ing its physiological barriers and eventually producing disease. Sub-
sequently, a complete understanding of pathogenesis of the particular
organism will undoubtly lead to the identification of potential thera-
peutic interventions.
Conflict of interests
The authors declare that there is no conflict of interests regarding
the publication of this paper.
Uncited references
[17]; [33]; [59]; [64]; [105]; [123]; [169]; [200].
Acknowledgments
This work was supported by Aga Khan University, Pakistan and
Sunway University, Malaysia.
References
[1] M.S. Abdel-Rhaman, W. Soliman, F. Habib, D. Fathalla, A new long-acting li-
posomal topical antifungal formula: human clinical study, Cornea 31 (2012)
126–129.
[2] H. Alizadeh, S. Apte, M.S. El-Agha, L. Li, M. Hurt, K. Howard, H.D. Ca-
vanagh, J.P. McCulley, J.Y. Niederkorn, Tear IgA and serum IgG antibodies
against Acanthamoeba in patients with Acanthamoeba keratitis,
Cornea 20 (2001) 622–627.
[3] H. Alizadeh, M.S. Pidherney, J.P. McCulley, J.Y. Niederkorn, Acanthamoeba
keratitis, in: J.S. Pepose, G.N. Holland, K.R. Wilhelmus (Eds.), Ocular Infec-
tion and Immunity, 1994a, pp. 1062–1071 (Mosby, St. Louis, Mo).
[4] H. Alizadeh, M.S. Pidherney, J.P. McCulley, J.Y. Niederkorn, Apoptosis as a
mechanism of cytolysis of tumor cells by a pathogenic free-living amoeba, In-
fect. Immun. 62 (1994b) 1298–1303.
[5] H. Alizadeh, S. Neelam, M. Hurt, J.Y. Niederkorn, Role of contact lens wear,
bacterial flora, and mannose-induced pathogenic protease in the pathogenesis
of amoebic keratitis, Infect. Immun. 73 (2005) 1061–1068.
[6] L.G. Alionte, B.M. Cannon, C.D. White, A.R. Caballero, R.J. O'Callaghan,
J.A. Hobden, Pseudomonas aeruginosa LasA protease and corneal infections,
Curr. Eye Res. 22 (2001) 266–271.
[7] Z. Ansari, D. Miller, A. Galor, Current thoughts in fungal keratitis: diagnosis
and treatment, Curr. Fungal Infect. Rep. 7 (2013) 209–218.
[8] R.A. Ansorg, M.E. Knoche, A.F. Spies, C.J. Kraus, Differentiation of the ma-
jor flagellar antigens of Pseudomonas aeruginosa by the slide coagglutination
technique, J. Clin. Microbiol. 20 (1984) 84–88.
[9] Y. Aqeel, R. Siddiqui, A. Anwar, M.R. Shah, S. Khoja, N.A. Khan, Pho-
tochemotherapeutic strategy against Acanthamoeba infections, Antimicrob.
Agents Chemother. 59 (2015) 3031–3041.
[10] P.A. Asbell, D.F. Sahm, M. Shaw, D.C. Draghi, N.P. Brown, Increasing preva-
lence of methicillin resistance in serious ocular infections caused by Staphylo-
coccus aureus in the United States: 2000 to 2005, J. Cataract. Refract
Surg. 34 (2008) 814–818.
[11] S. Bang, E. Edell, A.O. Eghrari, J.D. Gottsch, Treatment with voriconazole in
3 eyes with resistant Acanthamoeba keratitis, Am. J. Ophthalmol. 149 (2010)
66–69.
[12] J.P. Barletta, G. Angella, K.C. Balch, H.G. Dimova, G.A. Stern, M.T. Moser,
G.B. van Setten, G.S. Schultz, Inhibition of pseudomonal ulceration in rabbit
corneas by a synthetic matrix metalloproteinase inhibitor, Invest. Ophthalmol.
Vis. Sci. 37 (1996) 20–28.
[13] M.B. Berman, Regulation of corneal fibroblast MMP-1 collagenase secretion
by plasmin, Cornea 12 (1993) 420–432.
[14] M.J. Bharathi, R. Ramakrishnan, C. Shivakumar, R. Meenakshi, D. Lionalraj,
Etiology and antibacterial susceptibility pattern of community-acquired bacter-
ial ocular infections in a tertiary eye care hospital in south India, Indian J. Oph-
thalmol. 58 (2010) 497–507.
[15] J.M. Blondeau, Fluoroquinolones: mechanism of action, classification, and de-
velopment of resistance, Surv. Ophthalmol. 49 (Suppl 2) (2004) S73–S78.
[16] J.P. Bouchara, G. Tronchin, V. Annaix, R. Robert, J.M. Senet, Laminin recep-
tors on Candida albicans germ tubes, Infect. Immun. 58 (1990) 48–54.
[17] J.P. Bouchara, M. Sanchez, A. Chevailler, A. Marot-Leblond, J.C. Lissitzky,
G. Tronchin, D. Chabasse, Sialic acid-dependent recognition of laminin and
fibrinogen by Aspergillus fumigatus conidia, Infect. Immun. 65 (1997)
2717–2724.
[18] S.D. Boveland, P.A. Moore, J. Mysore, T.M. Krunkosky, U.M. Dietrich, C.
Jarrett, K. Paige Carmichael, Immunohistochemical study of matrix metallo-
proteinases-2 and -9, macrophage inflammatory protein-2 and tissue inhibitors
of matrix metalloproteinases-1 and -2 in normal, purulonecrotic and fungal in-
fected equine corneas, Vet. Ophthalmol. 13 (2010) 81–90.
[19] I.M. Bromley, K. Donaldson, Binding of Aspergillus fumigatus spores to lung
epithelial cells and basement membrane proteins: relevance to the asthmatic
lung, Thorax 51 (1996) 1203–1209.
[20] M. Busin, M. Spitznas, Sustained gentamicin release by presoaked medicated
bandage contact lenses, Ophthalmol 95 (1988) 796–798.
[21] A.R. Caballero, C.C. McCormick, A. Tang, R.J. O'Callaghan, Isolation and
characterization of a new Staphylococcus aureus protease, Invest. Ophthalmol.
Vis. Sci. 49 (2008) 5514.
[22] A.R. Caballero, T.J. Foster, I.R. Monk, A. Tang, C.L. Balzli, R.J. O'Callaghan,
Ocular pathology of a Staphylococcus aureus mutant lacking a recently discov-
ered virulence factor, Invest. Ophthalmol. Vis. Sci. 51 (2010) 3891.
[23] M.C. Callegan, L.S. Engel, J.M. Hill, R.J. O'Callaghan, Corneal virulence of
Staphylococcus aureus: roles of alpha-toxin and protein A in pathogenesis, In-
fect. Immun. 62 (1994) 2478–2482.
[24] Z. Cao, D.M. Jefferson, N. Panjwani, Role of carbohydrate-mediated adher-
ence in cytopathogenic mechanisms of Acanthamoeba, J. Biol.
Chem. 273 (1998) 15838–15845.
[25] W.L. Chen, C.Y. Wu, F.R. Hu, I.J. Wang, Therapeutic penetrating keratoplasty
for microbial keratitis in Taiwan from 1987 to 2001, Am. J. Ophthal-
mol. 137 (2004) 736–743.
[26] J. Cheung, A.R. Slomovic, Microbial etiology and predisposing factors among
patients hospitalized for corneal ulceration, Can. J. Ophthalmol. 30 (1995)
251–255.
[27] J.H. Cho, B.K. Na, T.S. Kim, C.Y. Song, Purification and characterization of
an extracellular serine proteinase from Acanthamoeba castellanii, IUBMB
Life 50 (2000) 209–214.
[28] B. Clarke, A. Sinha, D.N. Parmar, E. Sykakis, Advances in the diagnosis and
treatment of Acanthamoeba keratitis, J. Ophthalmol. (2012). Article ID:
484892.
[29] D.W. Clarke, J.Y. Niederkorn, The pathophysiology of Acanthamoeba kerati-
tis, Trends Parasitol. 22 (2006) 175–180.
UN
CO
RR
EC
TE
D
PR
OO
F
10 Microbial Pathogenesis xxx (2017) xxx-xxx
[30] D.W. Clarke, H. Alizadeh, J.Y. Niederkorn, Failure of Acanthamoeba castel-
lanii to produce intraocular infections, Invest. Ophthalmol. Vis. Sci. 46 (2005)
2472–2478.
[31] C.B.1 Cosar, E.J. Cohen, C.J. Rapuano, P.R. Laibson, Clear corneal wound in-
fection after phacoemulsification, Arch. Ophthalmol. 119 (2001) 1755–1759.
[32] D.J. Coster, P.R. Badenoch, Host, microbial, and pharmacological factors af-
fecting the outcome of suppurative keratitis, Br. J. Ophthalmol. 71 (1987)
96–101.
[33] J.W. Costerton, Pseudomonas aeruginosa in nature and diseases, in: L.D.
Sabath (Ed.), Pseudomonas aeruginosa: the Organisms, the Disease it Causes
and Their Treatment, Hans Huber, Bern, 1980. 1980.
[34] P. Coulot, J.P. Bouchara, G. Renier, V. Annaix, C. Planchenault, G. Tronchin,
D. Chabasse, Specific interaction of Aspergillus fumigatus with fibrinogen and
its role in cell adhesion, Infect. Immun. 62 (1994) 2169–2177.
[35] J.J. Dajcs, M.S. Austin, G.D. Sloop, J.M. Moreau, E.B. Hume, H.W. Thomp-
son, F.M. McAleese, T.J. Foster, R.J. O'Callaghan, Corneal pathogenesis of
Staphylococcus aureus strain Newman, Invest. Ophthalmol. Vis. Sci. 43 (2002)
1109–1115.
[36] J.K. Dart, V.P. Saw, S. Kilvington, Acanthamoeba Keratitis: diagnosis and
treatment update 2009, Am. J. Ophthalmol. 148 (2009) 487–499.
[37] J.F. De Jonckheere, Ecology of Acanthamoeba, Rev. Infect. Dis. 13 (Suppl 5)
(1991) S385–S387.
[38] R. Dudley, S. Alsam, N.A. Khan, The role of proteases in the differentiation of
Acanthamoeba castellanii, FEMS Microbiol. Lett. 286 (2008) 9–15.
[39] I.G. Duguid, J.K. Dart, N. Morlet, B.D. Allan, M. Matheson, L. Ficker, S. Tuft,
Outcome of Acanthamoeba keratitis treated with polyhexamethyl biguanide
and propamidine, Ophthalmol 104 (1997) 1587–1592.
[40] D.1 Dutta, N. Cole, M. Willcox, Factors influencing bacterial adhesion to con-
tact lenses, Mol. Vis. 18 (2012) 14–21.
[41] R.A. Eiferman, J.W. Snyder, Antibacterial effect of cyanoacrylate glue, Arch.
Ophthalmol. 101 (1983) 958–960.
[42] M.J. Elder, S. Kilvington, J.K. Dart, A clinicopathologic study of in vitro sen-
sitivity testing and Acanthamoeba keratitis, Invest. Ophthalmol. Vis.
Sci. 35 (1994) 1059–1064.
[43] A. Ellison, R. Poirier, Therapeutic effects of heparin on Pseudomonas-induced
corneal ulceration, Am. J. Ophthalmol. 82 (1976) 619–627.
[44] L.S. Engel, J.M. Hill, J.M. Moreau, L.C. Green, J.A. Hobden, R.J. O'-
Callaghan, Pseudomonas aeruginosa protease IV produces corneal damage and
contributes to bacterial virulence, Invest. Ophthalmol. Vis. Sci. 39 (1998)
662–665.
[45] R. Fitzsimons, A.L. Peters, Miconazole and ketoconazole as a satisfactory
first-line treatment for keratomycosis, Am. J. Ophthalmol. 101 (1986)
605–608.
[46] S.M. Fleiszig, T.S. Zaidi, M.J. Preston, M. Grout, D.J. Evans, G.B. Pier, Rela-
tionship between cytotoxicity and corneal epithelial cell invasion by clinical
isolates of Pseudomonas aeruginosa, Infect. Immun. 64 (1996) 2288–2294.
[47] M. Garate, Z. Cao, E. Bateman, N. Panjwani, Cloning and characterization of a
novel mannose-binding protein of Acanthamoeba, J. Biol. Chem. 279 (2004)
29849–29856.
[48] L. Garduño-Vieyra, C.R. Gonzalez-Sanchez, S.E. Hernandez-Da Mota, Ultra-
violet-a light and riboflavin therapy for Acanthamoeba keratitis: a case report,
Ophthalmol 118 (2011) 291–295.
[49] P. Garg, S. Chaurasia, P.K. Vaddavalli, R. Muralidhar, V. Mittal, U.
Gopinathan, Microbial keratitis after LASIK, J. Refract Surg. 26 (2010)
209–216.
[50] M.L. Gilbert, K.R. Wilhelmus, M.S. Osato, Intracanalicular collagen implants
enhance topical antibiotic bioavailability, Cornea 5 (1986) 167–171.
[51] N.S. Gokhale, Medical management approach to infectious keratitis, Indian J.
Ophthalmol. 56 (2008) 215–220.
[52] U. Gopinathan, T. Ramakrishna, M. Willcox, C.M. Rao, D. Balasubramanian,
A. Kulkarni, G.K. Vemuganti, G.N. Rao, Enzymatic, clinical and histologic
evaluation of corneal tissues in experimental fungal keratitis in rabbits, Exp.
Eye Res. 72 (2001) 433–442.
[53] U. Gopinathan, S. Sharma, P. Garg, G.N. Rao, Review of epidemiological fea-
tures, microbiological diagnosis and treatment outcome of microbial keratitis:
experience of over a decade, Indian J. Ophthalmol. 57 (2009) 273–279.
[54] B. Govindarajan, B.B. Menon, S. Spurr-Michaud, K. Rastogi, M.S. Gilmore,
P. Argüeso, I.K. Gipson, A metalloproteinase secreted by Streptococcus pneu-
moniae removes membrane mucin MUC16 from the epithelial glycocalyx bar-
rier, PLoS One 7 (2012) e32418.
[55] A. Gravet, D.A. Colin, D. Keller, R. Girardot, H. Monteil, G. Prévost, Charac-
terization of a novel structural member, LukE-LukD, of the bi-component
staphylococcal leucotoxins family, FEBS Lett. 436 (1998) 202–208.
[56] M. Green, A. Apel, F. Stapleton, Risk factors and causative organisms in mi-
crobial keratitis, Cornea 27 (2008) 22–27.
[57] F.S. Habib, E.A. Fouad, M.S. Abdel-Rhaman, D. Fathalla, Liposomes as an
ocular delivery system of fluconazole: in-vitro studies, Acta Ophthal-
mol. 88 (2010) 901–904.
[58] E. Hadas, T. Mazur, Proteolytic enzymes of pathogenic and non-pathogenic
strains of Acanthamoeba spp, Trop. Med. Parasitol. 44 (1993) 197–200.
[59] A.J. Hamilton, L. Jeavons, S. Youngchim, N. Vanittanakom, R.J. Hay, Sialic
acid-dependent recognition of laminin by Penicillium marneffei conidia, In-
fect. Immun. 66 (1998) 6024–6026.
[60] S. Hammerschmidt, Adherence molecules of pathogenic pneumococci, Curr.
Opin. Microbiol. 9 (2006) 12–20.
[61] S.M. Hariprasad, W.F. Mieler, T.K. Lin, W.E. Sponsel, J.R. Graybill,
Voriconazole in the treatment of fungal eye infections: a review of current lit-
erature, Br. J. Ophthalmol. 92 (2008) 871–878.
[62] J. Hay, C.M. Kirkness, D.V. Seal, P. Wright, Drug resistance and Acan-
thamoeba keratitis: the quest for alternative antiprotozoal chemotherapy, Eye
(Lond) 8 (1994) 555–563.
[63] L.D. Hazlett, M. Zucker, R.S. Berk, Distribution and kinetics of the inflamma-
tory cell response to ocular challenge with Pseudomonas aeruginosa in suscep-
tible versus resistant mice, Ophthalmic Res. 24 (1992) 32–39.
[64] L.D. Hazlett, Analysis of ocular microbial adhesion, Methods Enzy-
mol. 253 (1995) 53–66.
[65] Y.G. He, J.Y. Niederkorn, J.P. McCulley, G.L. Stewart, D.R. Meyer, R. Sil-
vany, J. Dougherty, In vivo and in vitro collagenolytic activity of Acan-
thamoeba castellanii, Invest. Ophthalmol. Vis. Sci. 31 (1990) 2235–2240.
[66] L.W. Heck, K. Morihara, W.B. McRae, E.J. Miller, Specific cleavage of hu-
man type III and IV collagens by Pseudomonas aeruginosa elastase, Infect. Im-
mun. 51 (1986) 115–118.
[67] A. Hejazi, F.R. Falkiner, Serratia marcescens, J. Med. Microbiol. 46 (1997)
903–912.
[68] M.K. Hostetter, Adhesins and ligands involved in the interaction of Candida
spp. with epithelial and endothelial surfaces, Clin. Microbiol. Rev. 7 (1994)
29–42.
[69] E.B. Hume, H. Zhu, N. Cole, C. Huynh, S. Lam, M.D. Willcox, Efficacy of
contact lens multipurpose solutions against serratia marcescens, Optom. Vis.
Sci. 84 (2007) 316–320.
[70] M. Hurt, J. Niederkorn, H. Alizadeh, Effects of mannose on Acanthamoeba
castellanii proliferation and cytolytic ability to corneal epithelial cells, Invest.
Ophthalmol. Vis. Sci. 44 (2003a) 3424–3431.
[71] M. Hurt, S. Neelam, J. Niederkorn, H. Alizadeh, Pathogenic Acanthamoeba
spp. secrete a mannose-induced cytolytic protein that correlates with the ability
to cause disease, Infect. Immun. 71 (2003b) 6243–6255.
[72] R.A. Hyndiuk, Experimental Pseudomonas keratitis: I. Sequential electron mi-
croscopy. II. Comparative therapy trials, Trans. Am. Ophthalmol.
Soc. 79 (1981) 541.
[73] Y.1 Ijiri, . Yamamoto, R. Kamata, H. Aoki, K. Matsumoto, R. Okamura, T.
Kambara, The role of Pseudomonas aeruginosa elastase in corneal ring abscess
formation in pseudomonal keratitis, Graefes Arch. Clin. Exp. Ophthal-
mol. 231 (1993) 521–528.
[74] C.D. Illingworth, S.D. Cook, Acanthamoeba keratitis, Surv. Ophthal-
mol. 42 (1998) 493–508.
[75] P. Imwidthaya, Mycotic keratitis in Thailand, J. Med. Vet. Mycol. 33 (1995)
81–82.
[76] A.A. Ismaiel, G.H. Rabie, S.E. Kenawey, M.A. Abd El-Aal, Efficacy of aque-
ous garlic extract on growth, aflatoxin B1 production, and cyto-morphological
aberrations of Aspergillus flavus, causing human ophthalmic infection: topical
treatment of A. flavus keratitis, Braz J. Microbiol. 43 (2012) 1355–1364.
[77] B.E. Jackson, K.R. Wilhelmus, B. Hube, The role of secreted aspartyl pro-
teinases in Candida albicans keratitis, Invest. Ophthalmol. Vis. Sci. 48 (2007)
3559–3565.
[78] V. Jain, A. Maiti, D. Shome, N. Borse, S. Natarajan, Aspergillus-induced ma-
lignant glaucoma, Cornea 26 (2007) 762–763.
[79] B.H. Jeng, D.C. Gritz, A.B. Kumar, D.S. Holsclaw, T.C. Porco, S.D. Smith,
J.P. Whitcher, T.P. Margolis, I.G. Wong, Epidemiology of ulcerative keratitis
in Northern California, Arch. Ophthalmol. 128 (2010) 1022–1028.
[80] B.D. Jett, M.S. Gilmore, Host-parasite interactions in Staphylococcus aureus
keratitis, DNA Cell Biol. 21 (2002) 397–404.
[81] C. Jiang, X. Sun, Z. Wang, Y. Zhang, Acanthamoeba keratitis: clinical charac-
teristics and management, Ophthalmol 113 (2006) 412–416.
[82] M.K. Johnson, M.C. Callegan, L.S. Engel, R.J. O'Callaghan, J.M. Hill, J.A.
Hobden, G.J. Boulnois, P.W. Andrew, T.J. Mitchell, Growth and virulence of a
complement-activation-negative mutant of Streptococcus pneumoniae in the
rabbit cornea, Curr. Eye Res. 14 (1995) 281–284.
[83] D.B. Jones, Decision-making in the management of microbial keratitis, Oph-
thalmol 88 (1981) 814–820.
[84] R. Kamata, K. Matsumoto, R. Okamura, T. Yamamoto, H. Maeda, The serra-
tial 56K protease as a major pathogenic factor in serratial keratitis. Clinical and
experimental study, Ophthalmol 92 (1985) 1452–1459.
[85] M. Kandori, T. Inoue, M. Shimabukuro, H. Hayashi, Y. Hori, N. Maeda, Y.
Tano, Four cases of Acanthamoeba keratitis treated with phototherapeutic ker-
atectomy, Cornea 29 (2010) 1199–1202.
[86] S. Kant, D. Srivastava, R.N. Misra, Toxic effects of aflatoxins on eyes–an ex-
perimental clinico-histopathological evaluation, Indian J. Ophthal-
mol. 32 (1984) 424–426.
[87] R.S. Karthikeyan, J.L. Priya, S.M. Leal Jr., J. Toska, A. Rietsch, V. Prajna, E.
Pearlman, P. Lalitha, Host response and bacterial virulence factor expression
UN
CO
RR
EC
TE
D
PR
OO
F
Microbial Pathogenesis xxx (2017) xxx-xxx 11
in Pseudomonas aeruginosa and Streptococcus pneumoniae corneal ulcers,
PLoS One 8 (2013) e64867.
[88] E. Kessler, H.E. Kennah, S.I. Brown, Pseudomonas protease. Purification, par-
tial characterization, and its effect on collagen, proteoglycan, and rabbit
corneas, Invest. Ophthalmol. Vis. Sci. 16 (1977) 488–497.
[89] N.A. Khan, Pathogenicity, morphology, and differentiation of Acanthamoeba,
Curr. Microbiol. 43 (2001) 391–395.
[90] N.A. Khan, Pathogenesis of Acanthamoeba infections, Microb.
Pathog. 34 (2003) 277–285.
[91] N.A. Khan, E.L. Jarroll, N. Panjwani, Z. Cao, T.A. Paget, Proteases as markers
for differentiation of pathogenic and nonpathogenic species of Acanthamoeba,
J. Clin. Microbiol. 38 (2000) 2858–2861.
[92] Y.A. Khan, R.T. Kashiwabuchi, S.A. Martins, J.M. Castro-Combs, S. Kalyani,
P. Stanley, D. Flikier, A. Behrens, Riboflavin and ultraviolet light a therapy as
an adjuvant treatment for medically refractive Acanthamoeba keratitis: report
of 3 cases, Opthalmol 118 (2011) 324–331.
[93] C.M. Kirkness, L.A. Ficker, A.D. Steele, N.S. Rice, The role of penetrating
keratoplasty in the management of microbial keratitis, Eye (Lond) 5 (Pt 4)
(1991) 425–431.
[94] H.1 Kiryu, S. Yoshida, Y. Suenaga, M. Asahi, Invasion and survival of Fusar-
ium solani in the dexamethasone-treated cornea of rabbits, J. Med. Vet. My-
col. 29 (1991) 395–406.
[95] A.S. Kreger, O.K. Griffin, Cornea-damaging proteases of Serratia marcescens,
Invest. Ophthalmol. 14 (1975) 190–198.
[96] A.S. Kreger, D.M. Lyerly, L.D. Hazlett, R.S. Berk, Immunization against ex-
perimental Pseudomonas aeruginosa and Serratia marcescens keratitis. Vacci-
nation with lipopolysaccharide endotoxins and proteases, Invest. Ophthalmol.
Vis. Sci. 27 (1986) 932–939.
[97] T. Kuriakose, P.A. Thomas, Keratomycotic malignant glaucoma, Indian J.
Ophthalmol. 39 (1991) 118–121.
[98] M. Labbate, H. Zhu, L. Thung, R. Bandara, M.R. Larsen, M.D. Willcox, M.
Givskov, S.A. Rice, S. Kjelleberg, Quorum-sensing regulation of adhesion in
Serratia marcescens MG1 is surface dependent, J. Bacteriol. 189 (2007)
2702–2711.
[99] P. Lalitha, B.L. Shapiro, M. Srinivasan, N.V. Prajna, N.R. Acharya, A.W.
Fothergill, J. Ruiz, J.D. Chidambaram, K.J. Maxey, K.C. Hong, S.D. McLeod,
T.M. Lietman, Antimicrobial susceptibility of Fusarium, Aspergillus, and other
filamentous fungi isolated from keratitis, Arch. Ophthalmol. 125 (2007)
789–793.
[100] A.K. Leck, P.A. Thomas, M. Hagan, J. Kaliamurthy, E. Ackuaku, M. John,
M.J. Newman, F.S. Codjoe, J.A. Opintan, C.M. Kalavathy, V. Essuman, C.A.
Jesudasan, G.J. Johnson, Aetiology of suppurative corneal ulcers in Ghana and
south India, and epidemiology of fungal keratitis, Br. J. Ophthalmol. 86 (2002)
1211–1215.
[101] G. Leema, J. Kaliamurthy, P. Geraldine, P.A. Thomas, Keratitis due to As-
pergillus flavus: clinical profile, molecular identification of fungal strains and
detection of aflatoxin production, Mol. Vis. 16 (2010) 843–854.
[102] Z. Li, V. Jhanji, X. Tao, H. Yu, W. Chen, G. Mu, Riboflavin/ultravoilet
light-mediated crosslinking for fungal keratitis, Br. J. Ophthalmol. 97 (2013)
669–671.
[103] T.J. Liesegang, Conjunctival changes associated with glaucoma therapy: impli-
cations for the external disease consultant and the treatment of glaucoma,
Cornea 17 (1998) 574–583.
[104] T. Lifshitz, J. Levy, I. Klemperer, Bacterial keratitis after laser subepithelial
keratectomy, J. Refract Surg. 21 (2005) 94–96.
[105] X. Liu, L. Hazlett, R. Berk, Systemic and topical protection studies using
Pseudomonas flagella or pili, Invest. Ophthalmol. Vis. Sci. 31 (1990) 449.
[106] J. Lorenzo-Morales, C.M. Martín-Navarro, A. López-Arencibia, F. Ar-
nalich-Montiel, J.E. Piñero, B. Valladares, Acanthamoeba keratitis: an emerg-
ing disease gathering importance worldwide?, Trends Parasitol. 29 (2013)
181–187.
[107] R. Lotti, J.K. Dart, Cataract as a complication of severe microbial keratitis,
Eye (Lond) 6 (Pt 4) (1992) 400–403.
[108] D. Lyerly, A. Kreger, Purification and characterization of a Serratia
marcescens metalloprotease, Infect. Immun. 24 (1979) 411–421.
[109] D. Lyerly, L. Gray, A. Kreger, Characterization of rabbit corneal damage pro-
duced by Serratia keratitis and by a serratia protease, Infect. Immun. 33 (1981)
927–932.
[110] A.M.A. Mahgoub, Acanthamoeba keratitis, Parasitol. Unit. J. 3 (2010) 9–18.
[111] F. Marciano-Cabral, G. Cabral, Acanthamoeba spp. as agents of disease in hu-
mans, Clin. Microbiol. Rev. 16 (2003) 273–307.
[112] F.B. Marangon, D. Miller, J.A. Giaconi, E.C. Alfonso, In vitro investigation of
voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens,
Am. J. Ophthalmol. 137 (2004) 820–825.
[113] M.E. Marquart, A.R. Caballero, M. Chomnawang, B.A. Thibodeaux, S.S.
Twining, R.J. O'Callaghan, Identification of a novel secreted protease from
Pseudomonas aeruginosa that causes corneal erosions, Invest. Ophthalmol.
Vis. Sci. 46 (2005) 3761–3768.
[114] M.E. Marquart, R.J. O'Callaghan, Infectious keratitis: secreted bacterial pro-
teins that mediate corneal damage, J. Ophthalmol. (2013). ID: 369094.
[115] K.B. Marty, C.L. Williams, L.J. Guynn, M.J. Benedik, S.R. Blanke, Character-
ization of a cytotoxic factor in culture filtrates of Serratia marcescens, Infect.
Immun. 70 (2002) 1121–1128.
[116] A.Y. Matoba, J.P. McCulley, The effect of therapeutic soft contact lenses on
antibiotic delivery to the cornea, Ophthalmol 92 (1985) 97–99.
[117] K.S. Mehra, R. Singh, R.P. Bhatia, P.C. Sen, H. Singh, Lysozyme in corneal
ulcer, Ann. Ophthalmol. 7 (1975) 1470–1472.
[118] G. Menestrina, M.D. Serra, G. Prévost, Mode of action of beta-barrel
pore-forming toxins of the staphylococcal alpha-hemolysin family, Toxi-
con 39 (2001) 1661–1672.
[119] M.M. Mitra, H. Alizadeh, R.D. Gerard, J.Y. Niederkorn, Characterization of a
plasminogen activator produced by Acanthamoeba castellanii, Mol. Biochem.
Parasitol. 73 (1995) 157–164.
[120] Y. Mochizuki, T. Suzuki, N. Oka, Y. Zhang, Y. Hayashi, N. Hayashi, N. Go-
toh, Y. Ohashi, Pseudomonas aeruginosa MucD protease mediates keratitis by
inhibiting neutrophil recruitment and promoting bacterial survival, Invest.
Ophthalmol. Vis. Sci. 55 (2014) 240–246.
[121] M. Mohammadinia, S. Rahmani, G. Eslami, M. Ghassemi-Broumand, M. Ag-
hazadh Amiri, G. Aghaie, S.M. Tabatabaee, S. Taheri, A. Behgozin, Contact
lens disinfecting solutions antibacterial efficacy: comparison between clinical
isolates and the standard ISO ATCC strains of Pseudomonas aeruginosa and
Staphylococcus aureus, Eye (Lond) 26 (2012) 327–330.
[122] E.K. Moon, S.H. Kim, Y. Hong, D.I. Chung, Y.K. Goo, H.H. Kong, Au-
tophagy inhibitors as a potential anti-amoebic treatment for Acanthamoeba
keratitis, Antimicrob. Agents Chemother. 59 (2015) 4020–4045.
[123] J.M. Moreau, G.D. Sloop, L.S. Engel, J.M. Hill, R.J. O'Callaghan, Histopatho-
logical studies of staphylococcal alpha-toxin: effects on rabbit corneas, Curr.
Eye Res. 16 (1997) 1221–1228.
[124] P.J. Morgan, S.C. Hyman, A.J. Rowe, T.J. Mitchell, P.W. Andrew, H.R.
Saibil, Subunit organisation and symmetry of pore-forming, oligomeric pneu-
molysin, FEBS Lett. 371 (1995) 77–80.
[125] M.E. Mulet, J.J. Pérez-Santonja, C. Ferrer, J.L. Alió, Microbial keratitis after
intrastromal corneal ring segment implantation, J. Refract Surg. 26 (2010)
364–369.
[126] L. Müller, M.A. Thiel, A.I. Kipfer-Kauer, C. Kaufmann, Corneal cross-linking
as supplementary treatment option in melting keratitis: a case series, Klin.
Monbl Augenheilkd 229 (2012) 411–415.
[127] F. Musa, R. Tailor, A. Gao, E. Hutley, S. Rauz, R.A. Scott, Contact lens-re-
lated microbial keratitis in deployed British military personnel, Br. J. Ophthal-
mol. 94 (2010) 988–993.
[128] J. Naginton, P.G. Watson, T.J. Playfair, J. McGill, B.R. Jones, A.D. Steele,
Amoebic infection of the eye, Lancet 2 (7896) (1974) 1537–1540.
[129] R.1 Nath, S. Baruah, L. Saikia, B. Devi, A.K. Borthakur, J. Mahanta, Mycotic
corneal ulcers in upper Assam, Indian J. Ophthalmol. 59 (2011) 367–371.
[130] J.Y. Niederkorn, H. Alizadeh, H. Leher, J.P. McCulley, The pathogenesis of
Acanthamoeba keratitis, Microbes Infect. 1 (1999) 437–443.
[131] E.W. Norcross, N.A. Tullos, S.D. Taylor, M.E. Sanders, M.E. Marquart, As-
sessment of Streptococcus pneumoniae capsule in conjunctivitis and keratitis
in vivo neuraminidase activity increases in nonencapsulated pneumococci fol-
lowing conjunctival infection, Curr. Eye Res. 35 (2010) 787–798.
[132] T.P. O'Brien, M.R. Sawusch, J.D. Dick, J.D. Gottsch, Topical ciprofloxacin
treatment of Pseudomonas keratitis in rabbits, Arch. Ophthalmol. 106 (1988)
1444–1446.
[133] T.P. O'Brien, Management of bacterial keratitis: beyond exorcism towards
consideration of organism and host factors, Eye (Lond) 17 (2003) 957–974.
[134] F.J. Ollivier, D.E. Brooks, G.B. Van Setten, G.S. Schultz, K.N. Gelatt, G.R.
Stevens, T.D. Blalock, S.E. Andrew, A.M. Komaromy, M.E. Lassaline, M.E.
Kallberg, T.J. Cutler, Profiles of matrix metalloproteinase activity in equine
tear fluid during corneal healing in 10 horses with ulcerative keratitis, Vet.
Ophthalmol. 7 (2004) 397. 405.
[135] L.D. Ormerod, E. Hertzmark, D.S. Gomez, R.G. Stabiner, D.J. Schanzlin, R.E.
Smith, Epidemiology of microbial keratitis in southern California, A Multivar.
anal. Ophthalmol. 94 (1987) 1322. 1333.
[136] M.L. Palmer, R.A. Hyndiuk, Contact lens-related infectious keratitis, Int. Oph-
thalmol. Clin. 33 (1993) 23–49.
[137] A. Panda, N. Sharma, S.K. Angra, Topical fluconazole therapy of Candida ker-
atitis, Cornea 15 (1996) 373–375.
[138] N. Panjwani, Pathogenesis of Acanthamoeba keratitis, Ocul. Surf. 8 (2010)
70–79.
[139] S. Pany, R. Vijayvargia, M.V. Krishnasastry, Caveolin-1 binding motif of al-
pha-hemolysin: its role in stability and pore formation, Biochem. Biophys.
Res. Commun. 322 (2004) 29–36.
[140] W.C. Parks, Matrix metalloproteinases in repair, Wound Repair Re-
gen. 7 (1999) 423–432.
[141] P.A. Parment, B. Colucci, B. Nyström, The efficacy of soft contact lens disin-
fection solutions against Serratia marcescens and Pseudomonas aeruginosa,
Acta Ophthalmol. Scand. 74 (1996) 235–237.
[142] P.A. Parment, The role of Serratia marcescens in soft contact lens associated
ocular infections. A review, Acta Ophthalmol. Scand. 75 (1997) 67–71.
UN
CO
RR
EC
TE
D
PR
OO
F
12 Microbial Pathogenesis xxx (2017) xxx-xxx
[143] M. Parta, Y. Chang, S. Rulong, P. Pinto-DaSilva, K.J. Kwon-Chung, HYP1, a
hydrophobin gene from Aspergillus fumigatus, complements the rodletless
phenotype in Aspergillus nidulans, Infect. Immun. 62 (1994) 4389–4395.
[144] A. Parthasarathy, D.T. Tan, Deep lamellar keratoplasty for Acanthamoeba ker-
atitis, Cornea 26 (2007) 1021–1023.
[145] J.C. Paton, B. Rowan-Kelly, A. Ferrante, Activation of human complement by
the pneumococcal toxin pneumolysin, Infect. Immun. 43 (1984) 1085–1087.
[146] D. Perrine, J.P. Chenu, P. Georges, J.C. Lancelot, C. Saturnino, M. Robba,
Amoebicidal efficiencies of various diamidines against two strains of Acan-
thamoeba polyphaga, Antimicrob. Agents Chemother. 39 (1995) 339–342.
[147] E. Pestova, R. Beyer, N.P. Cianciotto, G.A. Noskin, L.R. Peterson, Contribu-
tion of topoisomerase IV and DNA gyrase mutations in Streptococcus pneu-
moniae to resistance to novel fluoroquinolones, Antimicrob. Agents
Chemother. 43 (1999) 2000–2004.
[148] D.A. Pettit, J. Williamson, G.A. Cabral, F. Marciano-Cabral, In vitro destruc-
tion of nerve cell cultures by Acanthamoeba spp.: a transmission and scanning
electron microscopy study, J. Parasitol. 82 (1996) 769–777.
[149] M.S. Pidherney, H. Alizadeh, G.L. Stewart, J.P. McCulley, J.Y. Niederkorn, In
vitro and in vivo tumoricidal properties of a pathogenic/free-living amoeba,
Cancer Lett. 72 (1993) 91–98.
[150] G. Prakash, N. Sharma, M. Goel, J.S. Titiyal, R.B. Vajpayee, Evaluation of in-
trastromal injection of voriconazole as a therapeutic adjunctive for the manage-
ment of deep recalcitrant fungal keratitis, Am. J. Ophthalmol. 146 (2008)
56–59.
[151] M.O. Price, F.W. Price Jr., D. Maclellan, Effect of gatifloxacin 0.3% and mox-
ifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2
dosing regimens, J. Cataract. Refract Surg. 31 (2005) 2137–2141.
[152] C.F. Radford, O.J. Lehmann, J.K. Dat, Acanthamoeba keratitis: multicentre
survey in england 1992-6. National Acanthamoeba keratitis study group, Br. J.
Ophthalmol. 82 (1998) 1387–1392.
[153] G. Rajam, J.M. Anderton, G.M. Carlone, J.S. Sampson, E.W. Ades, Pneumo-
coccal surface adhesin A (PsaA): a review, Crit. Rev. Microbiol. 34 (2008)
163–173.
[154] S.K. Rao, H.N. Madhavan, G. Rao, P. Padmanabhan, Fluconazole in filamen-
tous fungal keratitis, Cornea 16 (1997) 700.
[155] J.C. Ramirez, S.M. Fleiszig, A.B. Sullivan, C. Tam, R. Borazjani, D.J. Evans,
Traversal of multilayered corneal epithelia by cytotoxic Pseudomonas aerugi-
nosa requires the phospholipase domain of exoU, Invest. Ophthalmol. Vis.
Sci. 53 (2012) 448–453.
[156] B.K. Rasool, H.M. Salmo, Development and clinical evaluation of clotrima-
zole-β-cyclodextrin eyedrops for the treatment of fungal keratitis, AAPS
PharmSciTech 13 (2012) 883–889.
[157] S.K.1 Raza, A.I. Mallet, S.A. Howell, P.A. Thomas, An in-vitro study of the
sterol content and toxin production of Fusarium isolates from mycotic keratitis,
J. Med. Microbiol. 41 (1994) 204–208.
[158] J.C. Reddy, M.D. Tibbetts, K.M. Hammersmith, P.K. Nagra, C.J. Rapuano,
Successful management of Burkholderia cepacia keratitis after LASIK, J. Re-
fract Surg. 29 (2013) 8–9.
[159] J.M. Reed, R.J. O'Callaghan, D.O. Girgis, C.C. McCormick, A.R. Caballero,
M.E. Marquart, Ocular virulence of capsule-deficient Streptococcus pneumo-
niae in a rabbit keratitis model, Invest. Ophthalmol. Vis. Sci. 46 (2005)
604–608.
[160] U. Rehany, G. Balut, E. Lefler, S. Rumelt, The prevalence and risk factors for
donor corneal button contamination and its association with ocular infection
after transplantation, Cornea 23 (2004) 649–654.
[161] M.N. Rhem, E.M. Lech, J.M. Patti, D. McDevitt, M. Höök, D.B. Jones, K.R.
Wilhelmus, The collagen-binding adhesin is a virulence factor in Staphylococ-
cus aureus keratitis, Infect. Immun. 68 (2000) 3776–3779.
[162] S. Romero-Steiner, T. Pilishvili, J.S. Sampson, S.E. Johnson, A. Stinson, G.M.
Carlone, E.W. Ades, Inhibition of pneumococcal adherence to human nasopha-
ryngeal epithelial cells by anti-PsaA antibodies, Clin. Diagn Lab. Im-
munol. 10 (2003) 246–251.
[163] R.H. Rosa Jr., D. Miller, E.C. Alfonso, The changing spectrum of fungal ker-
atitis in south Florida, Ophthalmol 101 (1994) 1005–1013.
[164] X.L. Rudner, Z. Zheng, R.S. Berk, R.T. Irvin, L.D. Hazlett, Corneal epithelial
glycoproteins exhibit Pseudomonas aeruginosa pilus binding activity, Invest.
Ophthalmol. Vis. Sci. 33 (1992) 2185–2193.
[165] J.R. Samples, P.S. Binder, F.J. Luibel, R.L. Font, G.S. Visvesvara, C.R. Peter,
Acanthamoeba keratitis possibly acquired from a hot tub, Arch. Ophthal-
mol. 102 (1984) 707–710.
[166] H.E. Schaeffer, D.L. Krohn, Liposomes in topical drug delivery, Invest. Oph-
thalmol. Vis. Sci. 22 (1982) 220–227.
[167] O.D. Schein, L.D. Ormerod, E. Barraquer, E. Alfonso, K.M. Egan, B.G. Paton,
K.R. Kenyon, Microbiology of contact lens-related keratitis, Cornea 8 (1989)
281–285.
[168] K. Scholtmeijer, J.G. Wessels, H.A. Wösten, Fungal hydrophobins in medical
and technical applications, Appl. Microbiol. Biotechnol. 56 (2001) 1–8.
[169] R.M. Shanks, N.A. Stella, E.J. Kalivoda, M.R. Doe, D.M. O'Dee, K.L. Lath-
rop, F.L. Guo, G.J. Nau, A Serratia marcescens OxyR homolog mediates sur-
face attachment and biofilm formation, J. Bacteriol. 189 (2007) 7262–7272.
[170] D.P. Sharma, S. Sharma, M.R. Wilkins, Microbial keratitis after corneal laser
refractive surgery, Future Microbiol. 6 (2011) 819–831.
[171] R. Siddiqui, N.A. Khan, Biology and pathogenesis of Acanthamoeba, Parasit.
Vectors 5 (2012) 6.
[172] H.H. Slansky, C.H. Dohlman, M.B. Berman, Prevention of corneal ulcers,
Trans. Am. Acad. Ophthalmol. Otolaryngol. 75 (1971) 1208–1211.
[173] P. Sony, N. Sharma, R.B. Vajpayee, M. Ray, Therapeutic keratoplasty for in-
fectious keratitis: a review of the literature, CLAO J. 28 (2002) 111–118.
[174] M.G. Speaker, F.A. Milch, M.K. Shah, W. Eisner, B.N. Kreiswirth, Role of ex-
ternal bacterial flora in the pathogenesis of acute postoperative endophthalmi-
tis, Ophthalmol 98 (1991) 639–649.
[175] E. Spoerl, M. Huhle, T. Seiler, Induction of cross-links in corneal tissue, Exp.
Eye Res. 66 (1998) 97–103.
[176] E. Spoerl, T. Seiler, Techniques for stiffening the cornea, J. Refract
Surg. 15 (1999) 711–713.
[177] E. Spoerl, G. Wollensak, T. Seiler, Increased resistance of crosslinked cornea
against enzymatic digestion, Curr. Eye Res. 29 (2004) 35–40.
[178] M. Srinivasan, Fungal keratitis, Curr. Opin. Ophthalmol. 15 (2004) 321–327.
[179] F. Stapleton, L.J. Keay, P.G. Sanfilippo, S. Katiyar, K.P. Edwards, T. Naduvi-
lath, Relationship between climate, disease severity, and causative organism
for contact lens-associated microbial keratitis in Australia, Am. J. Ophthal-
mol. 144 (2007) 690–698.
[180] F. Stapleton, N. Carnt, Contact lens-related microbial keratitis: how have epi-
demiology and genetics helped us with pathogenesis and prophylaxis, Eye
(Lond) 26 (2012) 185–193.
[181] S.S. Stopak, M.I. Roat, R.C. Nauheim, P.W. Turgeon, G. Sossi, R.P. Kowalski,
R.A. Thoft, Growth of Acanthamoeba on human corneal epithelial cells and
keratocytes in vitro, Invest. Ophthalmol. Vis. Sci. 32 (1991) 354–359.
[182] R.L. Sun, D.B. Jones, K.R. Wilhelmus, Clinical characteristics and outcome of
Candida keratitis, Am. J. Ophthalmol. 143 (2007) 1043–1045.
[183] A. Sy, M. Srinivasan, J. Mascarenhas, P. Lalitha, R. Rajaraman, M. Ravindran,
C.E. Oldenburg, K.J. Ray, D. Glidden, M.E. Zegans, S.D. McLeod, T.M. Liet-
man, N.R. Acharya, Pseudomonas aeruginosa keratitis: outcomes and response
to corticosteroid treatment, Invest. Ophthalmol. Vis. Sci. 53 (2012) 267–272.
[184] S. Szmigielski, G. Prévost, H. Monteil, D.A. Colin, J. Jeljaszewicz, Leukocidal
toxins of staphylococci, Zentralbl Bakteriol. 289 (1999) 185–201.
[185] E. Tacconelli, A.P. Johnson, National guidelines for decolonization of methi-
cillin-resistant Staphylococcus aureus carriers: the implications of recent expe-
rience in The Netherlands, J. Antimicrob. Chemother. 66 (2011) 2195–2198.
[186] A. Tang, M.E. Marquart, J.D. Fratkin, C.C. McCormick, A.R. Caballero, H.P.
Gatlin, R.J. O'Callaghan, Properties of PASP: a Pseudomonas protease capable
of mediating corneal erosions, Invest. Ophthalmol. Vis. Sci. 50 (2009)
3794–3801.
[187] M.A. Tanure, E.J. Cohen, S. Sudesh, C.J. Rapuano, P.R. Laibson, Spectrum of
fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania,
Cornea 19 (2000) 307–312.
[188] Y. Tatsumi, M. Nagashima, T. Shibanushi, A. Iwata, Y. Kangawa, F. Inui,
W.J. Siu, R. Pillai, Y. Nishiyama, Mechanism of action of efinaconazole, a
novel triazole antifungal agent, Antimicrob. Agents Chemother. 57 (2013)
2405–2409.
[189] S.A. Tayel, M.A. El-Nabarawi, M.I. Tadros, W.H. Abd-Elsalam, Positively
charged polymeric nanoparticle reservoirs of terbinafine hydrochloride: pre-
clinical implications for controlled drug delivery in the aqueous humor of rab-
bits, AAPS PharmSciTech 14 (2013) 782–793.
[190] W.M. Taylor, M.S. Pidherney, H. Alizadeh, J.Y. Niederkorn, In vitro charac-
terization of Acanthamoeba castellanii cytopathic effect, J. Parasitol. 81 (1995)
603–609.
[191] N. Thau, M. Monod, B. Crestani, C. Rolland, G. Tronchin, J.P. Latgé, S. Paris,
Rodletless mutants of Aspergillus fumigatus, Infect. Immun. 62 (1994)
4380–4388.
[192] B.A.1 Thibodeaux, A.R. Caballero, M.E. Marquart, J. Tommassen, R.J. O'-
Callaghan, Corneal virulence of Pseudomonas aeruginosa elastase B and alka-
line protease produced by Pseudomonas putida, Curr. Eye Res. 32 (2007)
373–386.
[193] P.A. Thomas, R.G. Garrison, T. Jansen, Intrahyphal hyphae in corneal tissue
from a case of keratitis due to Lasiodiplodia theobromae, J. Med. Vet. My-
col. 29 (1991) 263–267.
[194] P.A. Thomas, Mycotic keratitis–an underestimated mycosis, J. Med. Vet. My-
col. 32 (1994) 235–256.
[195] P.A. Thomas, Current perspectives on ophthalmic mycoses, Clin. Microbiol.
Rev. 16 (2003) 730–797.
[196] P.A. Thomas, J. Kaliamurthy, Mycotic keratitis: epidemiology, diagnosis and
management, Clin. Microbiol. Infect. 19 (2013) 210–220.
[197] S.J. Tilley, E.V. Orlova, R.J. Gilbert, P.W. Andrew, H.R. Saibil, Structural ba-
sis of pore formation by the bacterial toxin pneumolysin, Cell 121 (2005)
247–256.
[198] H. Trabelsi, F. Dendana, A. Sellami, H. Sellami, F. Cheikhrouhou, S. Neji, F.
Makni, A. Ayadi, Pathogenic free-living amoebae: epidemiology and clinical
review, Pathol. Biol. Paris. 60 (2012) 399–405.
UN
CO
RR
EC
TE
D
PR
OO
F
Microbial Pathogenesis xxx (2017) xxx-xxx 13
[199] G. Tronchin, J.P. Bouchara, R. Robert, J.M. Senet, Adherence of Candida albi-
cans germ tubes to plastic: ultrastructural and molecular studies of fibrillar ad-
hesins, Infect. Immun. 56 (1988) 1987–1993.
[200] G. Tronchin, M. Pihet, L.M. Lopes-Bezerra, J.P. Bouchara, Adherence mecha-
nisms in human pathogenic fungi, Med. Mycol. 46 (2008) 749–772.
[201] S.S. Twining, S.D. Davis, R.A. Hyndiuk, Relationship between proteases and
descemetocele formation in experimental Pseudomonas keratitis, Curr. Eye
Res. 5 (1986) 503–510.
[202] S.S. Twining, S.E. Kirschner, L.A. Mahnke, D.W. Frank, Effect of
Pseudomonas aeruginosa elastase, alkaline protease, and exotoxin A on corneal
proteinases and proteins, Invest. Ophthalmol. Vis. Sci. 34 (1993) 2699–2712.
[203] S.R. Unterman, D.S. Rootman, J.M. Hill, J.J. Parelman, H.W. Thompson, H.E.
Kaufman, Collagen shield drug delivery: therapeutic concentrations of to-
bramycin in the rabbit cornea and aqueous humor, J. Cataract. Refract
Surg. 14 (1988) 500–504.
[204] G.K. Vemuganti, P. Garg, U. Gopinathan, T.J. Naduvilath, R.K. John, R.
Buddi, G.N. Rao, Evaluation of agent and host factors in progression of my-
cotic keratitis: a histologic and microbiologic study of 167 corneal buttons,
Ophthalmol 109 (2002) 1538–1546.
[205] R. Vijayvargia, S. Kaur, N. Sangha, A.A. Sahasrabuddhe, I. Surolia, Y.
Shouche, M.V. Krishnasastry, Assembly of alpha-hemolysin on A431 cells
leads to clustering of Caveolin-1, Biochem. Biophys. Res. Com-
mun. 324 (2004) 1124–1129.
[206] G.S. Visvesvara, H. Moura, F.L. Schuster, Pathogenic and opportunistic
free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria
fowleri, and Sappinia diploidea, FEMS Immunol. Med. Microbiol. 50 (2007)
1–26.
[207] M.D. Wagoner, S.A. Al-Swailem, J.E. Sutphin, M.B. Zimmerman, Bacterial
keratitis after penetrating keratoplasty: incidence, microbiological profile, graft
survival, and visual outcome, Ophthalmol 114 (2007) 1073–1079.
[208] G. Wollensak, E. Spoerl, T. Seiler, Riboflavin/ultraviolet-a-induced collagen
crosslinking for the treatment of keratoconus, Am. J. Ophthalmol. 135 (2003)
620–627.
[209] V.W. Wong, T.Y. Lai, S.C. Chi, D.S. Lam, Pediatric ocular surface infections:
a 5-year review of demographics, clinical features, risk factors, microbiologi-
cal results, and treatment, Cornea 30 (2011) 995–1002.
[210] R.L. Wong, R.A. Gangwani, L.W. Yu, J.S. Lai, New treatments for bacterial
keratitis, J. Ophthalmol. (2012). ID:831502.
[211] P. Wright, D. Warhurst, B.R. Jones, Acanthamoeba keratitis successfully
treated medically, Br. J. Ophthalmol. 69 (1985) 778–782.
[212] L. Xie, H. Zhai, J. Zhao, S. Sun, W. Shi, X. Dong, Antifungal susceptibility for
common pathogens of fungal keratitis in Shandong Province, China, Am. J.
Ophthalmol. 146 (2001) 260–265.
[213] L. Xie, W. Zhong, W. Shi, S. Sun, Spectrum of fungal keratitis in north China,
Ophthalmol 113 (2006) 1943–1948.
[214] Y. Xu, C. Gao, X. Li, Y. He, L. Zhou, G. Pang, S. Sun, In vitro antifungal ac-
tivity of silver nanoparticles against ocular pathogenic filamentous fungi, J.
Ocul. Pharmacol. Ther. 29 (2013) 270–274.
[215] S. Yilmaz, I. Ozturk, A. Maden, Microbial keratitis in West Anatolia, Turkey:
a retrospective review, Int. Ophthalmol. 27 (2007) 261–268.
[216] K.C. Yoon, I.Y. Jeong, S.K. Im, H.J. Chae, S.Y. Yang, Therapeutic effect of
intracameral amphotericin B injection in the treatment of fungal keratitis,
Cornea 26 (2007) 814–818.
[217] W.S. Zhu, K. Wojdyla, K. Donlon, P.A. Thomas, H.I. Eberle, Extracellular
proteases of Aspergillus flavus. Fungal keratitis, proteases, and pathogenesis,
Diagn Microbiol. Infect. Dis. 13 (1990) 491–497.
